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2Abstract
Introduction: 
Individuals from older populations tend to have more than one health condition (multimorbidity). 
Current approaches to produce economic evidence for clinical guidelines using decision analytic 
models typically use a single-disease approach, which may not appropriately reflect the competing 
risks within a population with multimorbidity. This study aims to demonstrate a proof-of-concept 
method of modelling multiple conditions in a single decision-analytic model to estimate the impact 
of multimorbidity on the cost-effectiveness of interventions.  
Methods: 
Multiple conditions were modelled within a single decision-analytic model by linking multiple single-
disease models. Individual Discrete Event Simulation models were developed to evaluate the cost-
effectiveness of preventative interventions for a case study assuming a UK National Health Service 
perspective. The case study used three diseases (heart disease, Alzheimers disease, and 
osteoporosis) that were combined within a single linked model. The linked model, with and without 
correlations between diseases incorporated, simulated the general population aged 45 years and 
older to compare results in terms of lifetime costs and quality-adjusted life years (QALYs).
Results:
The estimated incremental costs and QALYs for healthcare interventions differed when three 
diseases were modelled simultaneously (£840; 0.234QALYs) compared with aggregated results from 
three single-disease models (£408; 0.280QALYs). With correlations between diseases additionally 
incorporated, both absolute and incremental costs and QALYs estimates changed in different 
directions, suggesting that the inclusion of correlations can alter model results.   
Discussion: 
Linking multiple single-disease models provides a methodological option for decision-analysts who 
undertake research on populations with multimorbidity.  It also has potential for wider applications 
in informing decisions on commissioning of healthcare services and long-term priority setting across 
diseases and healthcare programmes through providing potentially more accurate estimations of 
relative cost-effectiveness of interventions.
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Introduction
The prevalence of long-term conditions tends to steadily increase with age [1]. This trend results in 
an increased prevalence of multimorbidity, defined as the co-existence of two or more long-term 
health conditions, in populations of older people [2-4]. The increased proportion of individuals with 
multimorbidity may have a significant impact on healthcare and resource allocation decision-making 
[5-7]. Evidence suggests that the number of conditions, rather than specific diseases, is a greater 
determinant of use of healthcare service resources [2]. Multimorbidity is associated with increased 
healthcare costs, service use, mortality, and reduced quality of life than is the case for those of single 
conditions [3, 8, 9]. Some commentators have suggested the need to focus on the prevention and 
management of multimorbidity rather than of single diseases [10]. 
Despite the resource and health implications of multimorbidity, most economic evaluations are 
conceptualised and designed to evaluate the incremental costs and benefits (relative cost-
effectiveness) of interventions for single diseases [11] to recommend care and management for 
people with specific conditions. Decision-analytic models used to inform the Clinical Guidelines (CG) 
published by the National Institute for Health and Care Excellence (NICE) in England, and more 
widely [12-14], seldom consider people with multiple conditions [15]. Economic evidence for CG 
development is informed by a decision-analytic model (hereafter economic model) designed to 
appraise interventions to treat or manage adverse health events which are most likely to occur 
within the same (single) disease [16]. 
Consideration of multimorbidity in an economic model should potentially provide more reliable 
estimates than those from a single-disease approach. Consequently, taking account of 
multimorbidity should lead to improved decisions on adoption and implementation of interventions 
for populations with more than one conditions. Taking account of multimorbidity in a single model is 
likely to change the estimates of costs and quality-adjusted life years (QALYs) of treating and 
managing the diseases when compared with modelling separate multiple populations with single 
conditions [17]. Intuitively, the results from two or more separate disease models can be combined 
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4to obtain an understanding of the overall outcomes for a multi-morbid population. However, 
combining recommendations produced for single conditions to take account of multimorbidity may 
not represent the clinically optimal or cost-effective use of healthcare resources without jointly 
accounting for the benefits and risks of interventions [10, 18]. Such an approach does not 
incorporate competing risks of death nor does it account for the modification in the risks and health-
related quality of life (HRQoL) of the population with multimorbidity.   
This study aimed to present a proof-of-concept approach to taking account of multimorbidity in an 
economic model to generate robust estimates of incremental costs and health outcomes. The main 
focus was to present a methodology that could address multimorbidity within a single economic 
model by linking multiple single-disease models and, therefore, demonstrate the feasibility of using 
published models to incorporate multiple conditions within a single model. The method was 
illustrated using a case study of three selected diseases. The paper is now presented in three main 
sections. Section two describes the linkage methods used and the relevant case study. Section three 
reports the base-case results from the linked models, including a key finding associated with 
interpretation of result. Section four discusses the implications and limitations of using this approach 
in practice.  
Methods
 
This study demonstrates a method for linking multiple single-disease economic models using a 
Discrete Event Simulation (DES) constructed in SIMUL8 (©SIMUL8 Corporation). Three approaches 
to conceptualising and constructing an economic model were directly compared: (i) aggregating 
results from multiple single-disease models; (ii) modelling multiple diseases simultaneously within a 
single economic model; and (iii) incorporating correlations between diseases in the multi-disease 
economic model created in (ii). 
A case study was used to illustrate the methods. Multimorbidity was captured in the case study 
using three example diseases: heart disease (HD), Alzheimers disease (AD) and osteoporosis. Three 
diseases were selected to demonstrate the ability of the method to address any number of diseases 
that may co-occur. The selection of the relevant diseases to include in the case study was based on 
the economic, mortality and morbidity burden of each condition and the desire to cover a spectrum 
of conditions (see Appendix 1 for detailed selection criteria). A reference economic model to inform 
decisions on the structure, sources of data and key assumptions for each disease was identified from 
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5a rapid review of recently published economic models [19-21]. Using these economic models, the 
current recommended treatments for the three diseases (statins for HD; donepezil for mild to 
moderate AD and memantine for severe AD; and alendronic acid for osteoporosis) were compared 
with no drug treatment. The specific details of the case study and challenges associated with the 
application of the method are reported in Appendices 1-8.  
The analysis was undertaken from the perspective of UK National Health Service (NHS) and Personal 
Social Services (PSS) in line with the reference case stipulated by NICE [22]. A lifetime horizon was 
used to fully assess the long term effect of the interventions. Costs and health outcomes associated 
with a lifetime use of the interventions were presented in terms of pounds sterling (£ in 2012/13 
price) and QALYs, respectively. The relevant population was defined as the UK general population 
aged 45 years and over with or without the diseases, rather than only the elderly, to fully capture 
the prevention effect of the interventions. Age and gender values were randomly sampled from the 
UK mid-2012 population estimates [23]. Those individuals who did not have the disease may or may 
not develop it before death based on the age- and gender-stratified incidence of the disease. A 
discount rate of 3.5% per annum was used for both costs and QALYs. The next section describes the 
methods used to link multiple single-disease models in reference to the conventional DES approach.
Individual patient modelling methods
A DES approach was chosen for modelling the three diseases in which individual patients are 
simulated to move through different disease events sampled from time-to-event distributions. The 
selected diseases were modelled individually and then combined within a single DES model as a 
linked-disease economic model (see Figure 1). Potential correlations between the diseases were 
additionally explored in the linked-disease economic model. Figure 2 illustrates the method for 
model linkage with respect to simulation time.
===== Place Figure 1 here =====
======Place Figure 2 here=======
Individual patient modelling was used to provide more flexibility to incorporate heterogeneity 
among patients when compared with cohort modelling.  Whilst cohort-based models can 
theoretically account for different characteristics of individuals such as age, risk factors, and history 
of other diseases, the number of dimensions needed for the relevant health states become 
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6exponentially large [24]. The time-to-event approach used in DES provided a practical option for 
linking multiple diseases. Transition probabilities for pre-specified equal-length cycles as in state-
transition cohort (Markov) models are not required, allowing for greater flexibility in the times when 
events can occur. DES models can also record more individual attributes to account for patient 
history than Markov models: the rate of Event 1, , is updated once an individual 
experiences Event 2, such that .
Figure 2(a) represents an economic model for a disease shown as a course of changes over time in 
variables that define the modelled system (the process of disease progression). Figure 2(a-ii) 
depicts a Markov model in the same format as the DES model for a selected individual from a cohort. 
Any occurrences that alter any set of such variables can be considered as events. The variables 
describing the state of a disease process at a point in time include: global variables that apply to all 
simulated individuals (e.g. discount rates and unit costs of interventions); and individual attributes 
that may or may not change over time (e.g. age, sex and individuals disease history or changes in 
state membership if an individual from a Markov cohort is considered). The model outcomes such as 
lifetime costs and QALYs are based on the trajectories of these variables. Figure 2(a) shows how the 
DES allows for changes in the system variables to occur at any discrete point in time such that, 
multiple events can occur within a short period of time. The calculation of costs and QALYs is then 
made only when events occur, not at every cycle as in Markov models, hence allowing a large 
number of disease events to be incorporated in DES models. 
Modelling methods for linked model: general approach
The flexibility of the DES approach means that it is possible to merge existing single-disease 
economic models to create a linked-economic model by combining all event-defining variables 
within one system (see Figure 2(b)). In the linked economic models, costs were assumed to be 
additive. Four approaches (additive, minimum, multiplicative and linear index methods) to combine 
utility values for joint health conditions are possible in the absence of actual data for a population 
with more than one health condition. There is no agreement on the best approach and current 
recommendations suggest using the multiplicative method, which was the approach adopted in this 
study [25].   
Individuals with multiple diseases may have a higher risk of death. Multimorbidity is taken into 
account for disease-related death as competing risks: HD- and fracture-related deaths.  The earliest 
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7time to disease-related death was determined at the central router in the DES. Death may not be 
related to any of the diseases explicitly modelled. Non-disease mortality rates in the linked model 
were defined as all-cause mortality obtained from the UK Interim Life Tables [26] minus the death 
rates associated with the diseases included in the model. 
Two versions of the linked-economic model were constructed which assumed (i) independence 
between the three diseases; or (ii) correlation between the diseases. A probabilistic analysis was 
conducted using the linked economic model assuming correlation. Next section describes how the 
linked economic model assuming independence between the three diseases was constructed. 
Independence assumes that the presence of one disease does not affect the risk of the others 
(denoted hereafter as independently linked model).
Linked economic model: assuming independence
All variables used in the single-disease DES models (Figure 2(b-i)) were combined to produce the 
independently linked economic model (Figure 2(b-ii)). This approach unifies variables, such as age 
and gender, commonly included in all single-disease economic models (Figure 2(b-ii)). In the linked 
economic model, the sequence of events is redefined to represent the times when any variables 
combined in the linked model are scheduled to change (Figure 2(b-ii)).  Creating a linked economic 
model involves adding a central routing variable that directs simulated individuals to the earliest 
next event. This routing is done by taking a value indicating which of the diseases the identified next 
event is associated with (Figure 2(b-ii)).  Competing risks across all individual disease models can also 
be compared and individuals are directed to move to the event corresponding to the earliest 
scheduled time to event. This linked-economic model can provide a seamless approach especially 
when populations at increased risks of multimorbidity are modelled and when existing models are 
available for the individual diseases. 
Table 1 provides additional detail on the process used to update event times and routing. The table 
shows how to follow an individual through the DES from model entry. Individuals can have zero, one, 
two or three of the diseases, and enter the combined model with characteristics sampled at the 
entry point. These characteristics are used for the sampling of times to next event (TTNEs) and/or 
the calculation of aggregate costs and QALYs. Individuals enter the DES model through the central 
routing point where the transition to the next event is executed. Once the individuals move to the 
event and all relevant parameters are updated, they return to the central router to be routed to the 
Page 7 of 141
8next event. This process is repeated until an individual has been simulated up until the point at 
which they die. Recording the history of previous events means that the DES can account for 
multimorbidity, in terms of event costs, HRQoL and influence on risks of future events. The times to 
all further predicted events are then either resampled based on updated parameters or reduced by 
the TTNE to account for the passing of time. For example, at the central routing point, TTNEs for the 
other diseases are subtracted by the time spent in the previous event. Other time-related variables 
such as time before the effect of treatments stops, and time before the end of the first year of any 
cardiac events or osteoporotic fractures, are then re-calculated.   
===Place Table 1 here===
Linked economic model: assuming correlations between diseases 
This section describes how correlation between the three diseases was taken into account in the 
linked economic model.  Incorporating correlations between diseases assumes that having one 
disease can affect the risk of other diseases and hence correlations between diseases are 
incorporated (denoted hereafter as correlated linked economic model). The correlated linked 
economic model assigns disease history and event probabilities based on the status of the other 
diseases included in the DES model. Correlations associated with prevalence were incorporated to 
set the distribution of diseases at the start of the model, and correlations associated with incidence 
were used to dynamically change the incidence of one disease conditional on the occurrence of 
other disease events. 
The model assumed that the occurrence of HD events affects the incidence of AD, but not vice versa 
due to the relatively later onset of AD compared with that of HD [27]. There is growing evidence that 
supports osteoporosis is correlated with both HD and AD as greater vascular dysfunction is 
associated with lower bone mineral density [28-30]. Excess fracture risk has been reported among 
patients with a diagnosis of myocardial infarction with a hazard ratio of 1.73 [95% CI, 1.32-2.27] [31]. 
The DES assumed that a history of HD events would increase fracture risks and those with previous 
fracture would be at an increased risk of stroke and AD onset [31, 32].
For demonstrating a proof-of-concept model, correlations regarding selected prevalence and 
incidence estimates were deemed sufficient. Five types of correlations (see Appendix 2 for detail) 
were incorporated in the correlated linked model: i) prevalence and ii) incidence of AD in people 
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stroke among people with a history of hip fracture; and v) incidence of AD in people with low bone 
mineral density. Correlations associated with prevalence were incorporated at the start of the model 
by setting the distribution of diseases across individuals. Correlations associated with incidence were 
incorporated using a more dynamic approach. For example, after an individual develops an HD event, 
the incidence of AD for that individual was changed from the time of that HD event.  To incorporate 
the correlation between AD and HD, the total proportion of people who have AD was divided into 
the proportion of AD patients among people with HD and the proportion among people without HD. 
The incidence of AD for the total population was divided into that for population with HD and for 
population without HD, such that the sum of the incidence values equals the total incidence. 
 
Constructing single-disease models  
This section describes how the three single-disease economic models (heart disease, Alzheimers 
disease and osteoporosis) were conceptualised and built for the case study (see Figure 3). A rapid 
review was undertaken to identify economic models published as part of the UK National Institute 
for Health Research (NIHR) Health Technology Assessment (HTA) monograph series 
(https://www.journalslibrary.nihr.ac.uk/HTA/). Two of the three identified relevant single-disease 
models were Markov cohort models (HD and AD). The core structure of each identified economic 
model for each single disease was maintained but adapted to be implemented on a DES platform. 
Data sources reported in the published HTA reports were also used as model input parameters (see 
Appendix 3). All transition probabilities reported in the published economic models were converted 
to rates. Event rates reflect the instantaneous likelihood of the event occurring per unit of time. For 
each model, the appropriate number of simulated individuals to ensure stable outcomes was 
identified by examining the standard error of the mean estimates of (incremental) cost and QALYs, 
and the mean and jackknife confidence interval for the incremental cost per QALY estimate [33]. The 
results from the three single-disease models were compared with those of the published models to 
externally validate the model.
===== Place Figure 3 here=======
Page 9 of 141
10
Heart disease model
The state transition cohort model developed by Ward et al. [19], and used to inform guidance 
recommended by NICE, was used as the single disease model for heart disease (HD; Figure 3a). 
Statins, assuming a common class effect, were the intervention used for the secondary prevention of 
HD in patients with angina, MI, PAD or a history of stroke, and for primary prevention in patients 
who are at increased risk of coronary events. High-risk patients were defined as those whose 
estimated 10-risk of developing CVD is greater than 20% according to NICE TA94 [19]: however, the 
threshold was amended to 10% in 2014 [34].
Sources of data and key assumptions reported in Ward et al. [19] were considered as the main 
reference for the model. A review of existing models suggested that the single-disease economic 
model for HD should be adapted to include peripheral artery disease (PAD) and that it was necessary 
to update some parameter estimates (see Appendix 3).
First-year events and events in subsequent years were kept distinct because of the differences in the 
cost of interventions and HRQoL within these time periods. No difference in event rates was 
assumed between the first year and subsequent years after PAD because there was no clinical 
evidence identified distinguishing the two periods. The DES uses continuous time which means it 
was possible for an individual to have multiple events, and associated utility values, within a 12-
month period. It was therefore possible for one individual to incur two or more utility modifiers 
associated with first-year events. An event updating utility values was added to the model to ensure 
that changes in HRQoL were handled appropriately. 
Alzheimers disease
A DES model for Alzheimers disease (AD) was constructed (Figure 3b) based on the Markov model 
published in the HTA report by Bond et al. [20]. After a diagnosis of AD, the model structure 
replicated the three-state model in Bond et al. [20]. In line with current NICE recommendation [35], 
it was assumed that patients with a Mini-Mental State Examination (MMSE) score between 10 and 
26 at diagnosis (i.e. ,P MMSE P:98 received donepezil. Memantine was assumed for patients with 
MMSE < 10.
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A simulated population representative of the UK population aged 45 and over was assumed to enter 
the model. This analysis assumed that some individuals have AD when entering the model. Those 
entering the model without AD may or may not develop AD before death based on the sampled time 
to onset of AD. It was assumed that diagnosis of AD is not instantaneous as the development of 
symptoms is gradual.  
Osteoporosis model
The economic model produced by Stevenson et al. [21] was used as a basis for osteoporosis model 
constructed for the case study (see Figure 3c). 
Events included in the DES model for osteoporosis were defined by four index fracture sites (hip, 
vertebral, wrist and proximal humerus fractures) and the risks of: nursing home entry from hip 
fracture; death following fracture; and non-fracture related death. The events representing initiation 
and discontinuation of a preventative pharmacological intervention (70mg alendronate taken once 
weekly) were also included. The model included fractures occurring to both osteoporotic and non-
osteoporotic populations [21]. It was possible to have two first year utility multipliers acting 
simultaneously. An event to update utility values was included in the model to reflect that utilities 
for the first year and subsequent years after a fracture could be different. 
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Results
This section presents illustrative simulation results for the UK general population aged 45 years and 
older from the case study. The three single-disease models produced comparable results with those 
from the published reference models despite the difference in model populations (see Appendix 4). 
Results are reported from two types of linked models: those from the independently linked model; 
followed by those from the correlated linked model. For all results reported in this section, 
stochastic variability between simulated individuals was examined to ensure stable outcomes (see 
Appendix 5). 
Linked economic model: assuming independence 
Table 2 reports the base-case results from the linked economic model assuming independence 
between the three diseases. Incremental cost-per-QALY estimates for the three interventions 
(statins, donepezil or memantine, alendronate) for the three diseases in combination (HD, AD, 
osteoporosis, respectively) differed between the linked economic model and the individual disease 
DES models. There were higher incremental costs (£840) and lower incremental QALYs (0.234) in the 
linked economic model compared with the sum of the three single-disease model results (£408, 
0.280) (see Appendix 6). The absolute costs from the independently linked model (£14,776 for 
intervention arm) were slightly lower than the sum of the absolute costs from the three single-
disease models (£15,520). The absolute QALYs (8.956 for intervention arm) were also lower than the 
minimum of the equivalent values from the three individual disease models (9.249), as utility levels 
were generally lower in the model including multiple diseases than in the models that consider only 
one disease. 
=== Place Table 2 here ======
Table 3 presents incremental cost and QALYs, and cost per QALY estimates of each intervention 
(statins, donepezil or memantine, alendronate) from the independently linked model based on 
700,000 simulated individuals. This analysis assumed that the interventions for the other two 
conditions were available to individuals. The results differed from the results from the single disease 
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models: the linked model produced larger incremental costs and smaller incremental QALYs in 
absolute values than the single disease models (see Appendix 6).
This difference was most noticeable for AD intervention which produced lower QALYs with lower 
costs than no treatment in the linked model (incremental QALYs of -0.001; incremental cost of -£24) 
whilst it was dominating no treatment in the individual AD model (Appendix 6). The results in Table 3 
did not have face validity because it was not considered plausible to have negative incremental 
QALYs associated with AD intervention: donepezil or memantine only delays cognitive impairment 
and the model did not capture the impact of adverse drug events. Therefore, the number of 
simulated individuals was increased to two million, from 700,000, individuals, and then face validity 
improved with the AD intervention dominating no treatment with a very small QALY gain. The small 
incremental values were in line with the results from the Bond et al. study [20, 36]. 
=== Place Table 3 here======
Impact of imbalance between the linked diseases on the interpretation of the 
results
Making a direct comparison between the absolute size of incremental QALYs and costs per person 
across the single-disease economic models (Figure 4 and Appendix 6), it is clear that the effect of HD 
intervention was much larger than those interventions for AD or osteoporosis. The results were 
shown to be stable within individual disease models. The relative cost-effectiveness of individual 
interventions estimated from the linked economic model could potentially be affected by the level 
of balance between the size of QALYs and cost outcomes from the individual diseases included in the 
linked economic model (regardless of whether independence or correlation was assumed). This 
effect was observed when the QALY gains from one disease (in the case study, HD) were much larger 
than those for the remainder and there were different levels of Monte Carlo sampling error between 
diseases. Hence, an acceptable level of sampling error in one disease for robust adoption decision 
for that disease could significantly impact the QALYs and cost outcomes for the other diseases.  
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====Place Figure 4 here=====
The margin of error, defined as half-width of the 95% confidence interval in this study, around the 
mean incremental QALYs, was used to describe the amount of random sampling error in the 
simulation results [37].  In the individual HD model, the margin of error was estimated to be 0.0288 
QALYs based on 200,000 simulated individuals. To estimate the predicted margin of error of the 
mean incremental QALYs with increased number of simulated individuals (N), a power regression 
model was used to fit a non-linear curve that decreases proportionally by  (R2=0.9999). Using the 
fitted equation, the margin of error in incremental QALYs for HD intervention with 700,000 
individuals was predicted to be 0.0155 QALYs. With 10 million individuals simulated, this value 
(0.0042 QALYs) was still large compared with the incremental QALYs associated with the 
interventions for AD (0.001 QALYs) and osteoporosis (0.008 QALYs). This shows that, where the 
treatment of one disease has a much larger absolute impact on cost and QALYs than the impact of 
treatments for other, a very large number of individuals may need to be simulated for stable results 
to be achieved in a linked model. Appendix 7 describes a hypothetical scenario in which a similar 
level of QALY gains was assumed for all three interventions, and the adoption decision within the 
linked model for each individual intervention was robust.  
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Linked economic model: assuming correlation between diseases
Table 4 reports the base-case results from the linked economic model incorporating correlations. 
The incremental cost-per-QALY results for the combination of the three interventions were similar to 
the results from the independently linked model (£3,583 per QALY gained). When the three diseases 
were assumed to be correlated, the absolute values of QALYs and life years increased and costs were 
lower.  This was the result of positive correlations between diseases resulting in multimorbidity 
being more concentrated within a narrower population. Table 5 shows the results of running the 
model with two million individuals simulated to reduce the impact of the aforementioned sampling 
error issue. A probabilistic sensitivity analysis (PSA) using the correlated linked model was 
undertaken and its feasibility in the multi-disease DES context is discussed in Appendix 8. All of the 
300 PSA samples showed incremental cost-per-QALY being lower than the threshold of £20,000 per 
QALY gained (Figure S8.1, Appendix 8). Conducting 300 PSA runs required 1.9 days of computing 
time for each intervention arm (Intel CoreTM i7CPU 3.40GHz processor with 16GB RAM). 
===Place Table 4 here=====
==== Place Table 5 here=====
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Discussion
This study aimed to demonstrate a proof-of-concept method to link multiple single-disease models 
using a case study involving three diseases (HD, AD and osteoporosis) managed with three 
interventions (statins, donepezil or memantine, alendronate). The inclusion of multiple diseases in a 
single DES model also enabled correlation between the diseases to be incorporated.  This illustrative 
example showed that producing a linked economic model was feasible using DES and also allowed a 
PSA to be performed. The results from the three single-disease models were broadly comparable 
with those from the published economic models despite differences in model populations, costs and 
health events included (Appendix 4).  The linked economic model results showed that incorporating 
multiple diseases and correlations between them in a model can produce different estimates of 
aggregate costs and QALYs for a disease when compared with those estimates derived from single-
disease models. In general, the magnitude of the difference between single and linked model results 
increased with the proportion of the model population developing multiple diseases. These results 
confirm a priori expectations that when considering a population of individuals that are susceptible 
to multiple health conditions, producing an economic model that focusses on a single disease will 
not only misrepresent actual care pathways but seriously bias the estimated costs and QALYs. 
Consequently, an intervention could be mistakenly estimated to be cost-effective when it is not. This 
potential for bias is relevant in the context of both allocation of healthcare resources and clinical 
guidelines. An economic model that appropriately links multiple diseases is likely to produce 
different decisions on technology adoption, which in turn could alter the nature of the NHS funded 
treatment options made available in clinical practice [38, 39].
To be able to appropriately measure the impact of multimorbidity, it is necessary to carefully select 
the relevant co-existing diseases for a specified decision problem. Ideally, the use of pre-defined 
criteria (as exemplified in Appendix 1) should be used to guide the selection of relevant diseases.  
Careful consideration should be paid to how many of the relevant diseases should be included in a 
linked economic model. The same principles used for single-disease modelling also apply to the 
selection of multiple diseases: the diseases considered to alter model outcomes that are important 
for the population being studied and to policy makers (such as costs and QALYs) should be included. 
Epidemiological data that identify commonly co-existing health conditions (for example, see [10]) 
can be used to inform the choice of which diseases are most relevant. The assessment of marginal 
returns to adding more diseases in the linked model could be investigated empirically. 
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This proof-of-concept analysis suggested that when one disease had a much larger impact on costs 
and QALYs than the other diseases in a linked economic model, the sampling error around the 
disease with larger impact could make a significant difference to the estimated cost-effectiveness of 
the other individual treatments. This result could lead to lack of face validity for the diseases with 
smaller incremental gains. The implication is that the number of simulated patients required to 
stabilise the adoption decisions within linked economic models may be greater than the maximum 
of the numbers required for single-disease models. In circumstances where the QALY gains are 
similar across individual treatments, then it is likely that the proposed methods of linking single 
disease models produce more accurate estimates for multi-morbid populations. Further research on 
approaches to addressing this problem, in particular when incremental costs and QALYs are small in 
magnitude, would be beneficial.
The analysis showed that including correlations between diseases may potentially change the 
relative cost-effectiveness of interventions. When correlations were implemented, absolute QALYs 
were higher than when the diseases were assumed independent due to the concentration of co-
morbidities onto an already diseased population, resulting in lower QALY loss from having an 
additional disease. Hence, adding correlations better reflects the relationship between 
multimorbidity and mortality.  This paper demonstrated how to include correlations, based on the 
currently available data. Further evidence on correlations between diseases may become available in 
the future which would allow the model to be extended and improved.   
The DES approach, as illustrated in this paper, showed how it was sufficiently flexible to allow the 
impact of different types of individuals in a population to be quantified.  The general population was 
used as the entry population in the DES model, but it is possible to define more specific populations 
with different distributions of individual characteristics, for example, a population of individuals with 
prevalent HD but without osteoporosis.  In turn, a particular health intervention could be evaluated 
for these individuals in a population, which mirrors the approach in conventional HTA analyses for 
interventions in single diseases. 
There were some limitations to this proof-of-concept method. The use of the DES framework 
enabled the seamless linkage of the three disease distinct economic models, but future work could 
explore the application of the linkage method using methods other than DES. Also, the multiplicative 
method was used to combine utility values for the co-occurring health conditions. There are three 
other possible methods: additive, minimum and linear index methods. Each of these methods is 
likely to produce different utilities for any combination of health states, but the direction of the 
changes in the observed utility values will be the same. A future study could investigate the impact 
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of  using different methods to combine utility values on the magnitude of the cost-effectiveness of 
interventions in a linked model for more than one disease [40].
In this proof-of-concept study, time-to-event distributions and random numbers were used to 
represent the variability among individual observations (first-order uncertainty) as reported in 
Appendix 5.  Uncertainty around the structure of the economic model was not examined. A 
probabilistic sensitivity analysis (PSA) is required to understand the impact of second-order 
uncertainty arising from uncertainty in the model input parameters [41].  A feasibility run of PSA was 
undertaken that showed significant model running time would be required to conduct a large-scale 
PSA for this model (Appendix 8).   A study designed to understand the impact of parameter and 
structural uncertainty in a linked economic model could be a topic for future research using parallel 
computing or expedited PSA with non-parametric regression modelling [42]. Also, running the model 
for a more narrowly defined population with specific characteristics and higher disease prevalence, 
rather than for the general population, would accelerate convergence to mean outcomes at each 
deterministic run.
In conclusion, this proof-of-concept study used DES to produce a linked economic model and 
demonstrated that this is a feasible approach to inform decision-making relevant to interventions for 
populations with multimorbidity. This study provided a modelling framework that has the potential 
to be modified and/or expanded to incorporate other diseases and interventions to inform the 
development of clinical guidelines using evidence about the relative cost-effectiveness of 
interventions for people with multimorbidity. This study has shown that using a linked economic 
model that incorporates correlations between diseases is likely to influence the potential decisions 
made about the allocation of healthcare resources to support interventions relevant to multi-morbid 
populations, increasing the health benefits experienced by those patients.
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Table 1. An illustration of individuals movement through the linked model  
Simulation 
time
Location (Event 
where updates 
occur)
Time to next disease event
Time 0 Entry Time to next heart disease event: Sampled to be 2.5 years
Time to next Alzheimers disease event: Sampled to be 12 
years 
Time to next osteoporosis event: Sampled to be 4.5 years
Time 0 Central router  Time to next event: 2.5 years (heart disease event)
 Utility weight until next event: 0.85 (baseline utility)
Time 2.5 Heart disease 
event
Next heart disease event: Sampled to be 6.8 years
Time 2.5 Central router Next heart disease event: 6.8 years
Next Alzheimers disease event: Updated to 9.5 (12-2.5) 
years
Next osteoporosis event: Updated to 2 (4.5-2.5) years
 Time to next event: 2 years (osteoporosis event)
 Utility weight until next event: 0.595 [=0.85 
(baseline utility) x 0.7 (utility multiplier for heart 
disease events)]
Time 4.5 Osteo event Next osteoporosis event: Sampled to be 7.3 years
Time 4.5 Central router Next heart disease event: Updated to 4.8 (6.8-2) years
Next Alzheimers disease event: Updated to 7.5 (9.5-2) years 
Next osteoporosis event: 7.3 years
 Time to next event: 4.8 years (heart disease)
 Utility weight until next event: 0.476 [=0.85 
(baseline) x 0.7 (heart disease) x 0.8 (utility 
multiplier for osteoporosis events)]
Time 9.3 Heart disease 
event
Next heart disease event: Sampled to be 8.2 years
Time 9.3 Central router Next heart disease event: 8.2 years
Next Alzheimers disease event: Updated to 2.7 (7.5-4.8) 
years 
Next osteoporosis event: Updated to 2.5 (7.3-4.8) years
 Time to next event: 2.5 years (osteoporosis)
 Utility weight until next event: 0.476 [=0.85 
(baseline) x 0.7 (heart disease) x 0.8 (osteoporosis)
7
The process continues until death
*For illustration, the same utility values were assumed across all events within one disease: 0.7 for heart disease events 
and 0.8 for osteoporosis events. A constant baseline utility weight of 0.85 was assumed; When the same event occurs 
more than once (e.g. two strokes within a year), a utility multiplier is applied only once. 
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Table 2. Per-capita results from the independently linked model based on n=700,000 simulated 
individuals
Independently linked model Individual disease 
models
With all 
trea  
None of the 
three 
treatments
Incremental 
values
Sum of incremental 
values across three 
individual models
Cost £ 14,776 £ 13,936 £ 840 £ 408
QALYs 8.956 8.722 0.234 0.280
ICER   £ 3,582 /QALY £ 1,458
*All the default treatments were assumed to be available.
Table 3. Cost-effectiveness of individual treatments from the all-disease linked model where 
diseases were assumed independent 
HD treatment AD treatment Osteoporosis treatmentAll disease 
linked 
model
No HD 
treatment* 
Incremental 
values**
No AD 
treatment*
Incremental 
values**
No Osteo-
porosis 
treatment*
Incremental 
values**
Based on 700,000 simulated individuals
Cost
£ 13,815 £ 960 £ 14,800 -£ 24 £ 14,942 -£ 166
QALYs
8.720 0.236 8.957 -0.001 8.954 0.002
ICER £ 4,068 £ 32,549 Dominating
Based on 2,000,000 simulated individuals
Cost
£ 13,798 £ 1,004 £ 14,819 -£ 18 £ 14,914 -£ 112
QALYs
8.717 0.240 8.958 0.000 8.952 0.005
ICER £ 4,175 Dominating Dominating
HD=heart disease; AD=Alzheimers disease; *Treatments for the remaining two diseases were assumed to be 
available; **All incremental values are compared with the results with all three treatments available; 
Treatment with lower costs and lower QALYs; Costs and QALYs discounted at 3.5% p.a.
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Table 4. Base-case results from the all-disease model with correlations between diseases 
incorporated based on n=700,000 simulated individuals
Linked model with correlations incorporated
With all three 
treatments* 
None of the three 
treatments
Incremental values 
Cost £ 14,741 £ 13,894  £ 847
QALYs 8.962 8.725 0.236
ICER  £3,583 /QALY
*All the default treatments were assumed to be available.
Table 5. Cost-effectiveness of individual treatments using results from the all-disease linked model 
with correlations incorporated, based on n=2,000,000 simulated individuals
HD treatment AD treatment Osteoporosis treatment
No HD 
treatment*
Incremental 
values**
No AD 
treatment*
Incremental 
values**
No 
Osteoporosis 
treatment*
Incremental 
values**
Cost
£ 13,791 £ 936 £ 14,742 -£ 15 £ 14,869 -£ 142
QALYs
8.730 0.235 8.963 0.002 8.961 0.004
ICER
(£/QALY)
£ 3,978 Dominating Dominating 
HD=heart disease; AD=Alzheimers disease; *Treatments for the remaining two diseases were assumed to be 
available; **All incremental values are compared with the results with all three treatments available. 
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 Figure 2. Discrete event simulation (DES) model with and without model linkage 
All y-axes of the diagrams show examples of variables defining the respective models and changes in their 
values over simulation time (x-axes); *Global parameters: variables that apply to all simulated individuals 
such as discount rates, unit cost of interventions and utility associated with health events; **Individual 
attributes: variables that reflect changes in individual characteristics over time such as age, a previous 
experience of disease events and utility multipliers relevant to the individual at specific event times; 
Central routing variable was added after combining all single-disease model variables in the linked model 
to indicate in which disease model the next event is scheduled to occur. 
254x190mm (96 x 96 DPI) 
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2Appendix 1. Justification for disease selection
The criteria used for selecting the diseases to be modelled in the case study are summarised in Box 1. 
Box 1. Criteria for selecting diseases to model
o Diseases with major cost implications: High costs to the UK NHS and Personal Social Services 
of treating/managing the diseases
o Diseases of the elderly: Diseases with significant mortality and morbidity burden for older 
population and diseases whose incidence is expected to increase as population ages.
o Establishing a balance between different disease areas in order to cover a spectrum of 
conditions.
o Diseases that are correlated with respect to their incidence/prevalence and thus are more 
likely to co-occur
o Whether there are sufficiently recent HTA reports undertaken for the disease in order that a 
peer-reviewed model could be replicated.
o Diseases of hard endpoints, rather than those being risk factors for other diseases 
themselves, such as diabetes and hypertension
Diseases with significant cost implications to the UK NHS and Personal Social Services (PSS) for an 
ageing population were considered for inclusion in the model. Diseases expected to become more 
prevalent as a population ages were given a priority. 
A balance between different disease areas was also considered as one of the criteria. Including 
diseases from one or two areas of diseases whose mechanisms are similar may be misleading in 
estimating the broad impact of population ageing on healthcare expenditure and the interactions 
between diseases. Among diseases of significant economic, mortality and morbidity burdens, a 
spectrum of diseases that affect different parts of the body were included. 
Diseases that are potentially correlated were considered for inclusion in the case study. Seemingly 
unrelated health conditions may co-occur in individuals as they often share common underlying risk 
factors (for further details, see Appendix 2). 
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3Fracture risks are influenced by the presence of cardiovascular disease (CVD).  In a study that was a 
part of the Rochester Epidemiology Project, myocardial infarction (MI) was associated with higher 
risk of all types of osteoporotic fracture [1]. Excess fracture risks after MI were found with the 
overall adjusted hazard ratio (HR) of 1.32 (95% CI 1.12-1.56) across all anatomic sites. 
Further, the prevalence of heart disease (HD) among Alzheimers disease (AD) patients was 
considered higher than that of HD within an age- and gender-matched general population.  A 
number of studies have found that AD often co-exists with vascular conditions such as hypertension, 
hyper-cholesterolaemia, and diabetes mellitus [2-6]. 
Osteoporosis and stroke share several risk factors, including age, smoking, low physical activity, and 
hypertension. Thus, low bone mineral density (BMD) and high stroke risk can be correlated. Studies 
have shown that low BMD or a history of fracture has an association with the incidence of stroke [7-
9]. Jørgensen et al. [9] reported that women with BMD values in the lowest quartile had a higher risk 
of stroke than women with BMD values in the highest quartile (odds ratio (OR)= 4.8), and a linear 
trend over the quartiles was statistically significant. The OR for stroke increased 1.9 per SD (0.13 
g/cm2) reduction in BMD. The association between low BMD and stroke in women remained 
significant when the analysis was adjusted for potential confounders. In men, however, no 
statistically significant difference in BMD between the stroke patients and their controls was found.  
The presence of recently published (or in press) NIHR HTA reports was considered as it was deemed 
as evidence of the importance of the disease to major stakeholders such as decision-makers in local 
government, policy-makers (including the National Institute for Health and Care Excellence (NICE)), 
health professionals, and the general public. Further, the model structures reported in the HTA 
reports were largely replicated. 
Diseases with hard endpoints were preferred to those which were surrogate risk factors for other 
diseases. It was believed that such diseases could be embedded as a risk factor, and the 
consequences of the diseases could be represented in the models of other diseases. 
Using the selection criteria, the three diseases with significant mortality and disability burdens for 
the elderly  heart disease (including stroke and MI), Alzheimers disease, and osteoporosis  were 
chosen for the case study.  
The most expensive disease category was cardiovascular disease.  Heart conditions, such as coronary 
heart disease (CHD) and MI, and stroke were selected for modelling as they account for the largest 
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4proportion of mortality and prevalent cases in cardiovascular disease among older individuals [10], 
and impose significant economic burden on the overall healthcare system [11]. 
Dementia was selected for modelling considering its cost, potential association with CVD, the 
balance between the chosen diseases, and likely impact of population ageing. Amongst brain 
disorders, dementia was the most expensive category of spending [12], and affects older people in 
particular with the incidence positively correlated with age [13]. Only the most common form of 
dementia, Alzheimers disease (AD), was modelled in this study as the current NICE guidance and 
relevant model-based studies (including HTA reports) focussed on AD.
It was considered appropriate to include one or more musculoskeletal disorders due to the 
increasing prevalence and incidence with age. Amongst the musculoskeletal conditions, osteoporosis 
was deemed appropriate to include in the model due to its high cost.  Osteoarthritis (OA) was not 
selected as previous models have been built for OAs at different anatomical sites such as knees, hips, 
and joints of hands, which make OA more difficult to include given the aim of this paper. 
Furthermore, the incidence of OA is difficult to estimate as the onset is not well-defined due to the 
discrepancy between the symptomatic OA and OA based on the radiological changes.  Rheumatoid 
arthritis (RA) was considered for inclusion as RA mainly affects people aged 65 years and older [14]. 
However, RA was not chosen for the modelling given that the cost of RA did not exceed that of OA 
and chronic obstructive pulmonary disease. 
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2Appendix 2. Incorporating correlations between diseases
The following correlations were incorporated in the proof-of-concept model.
1) Prevalence of AD for people with and without HD
2) Incidence of AD for people with and without HD
3) Incidence of hip fracture for people with and without a history of MI
4) Stroke risks among people with and without a history of hip fracture
5) Incidence of AD with and without low BMD
AD=Alzheimers disease; HD= heart disease; MI= myocardial infarction; BMD=bone mineral density
This section describes only the correlations between the prevalence of HD and AD ((1) in above table) 
and the incidence of osteoporotic fracture and the presence of HD ((3) in above) incorporated in the 
linked model and how these correlations were implemented. The correlations 1)-5) were selected 
due to the data availability. Different incidence and prevalence estimates were applied to two 
groups of people with and without the other underlying condition.  Similar calculation methods to 
those described in this section were applied to other correlations. 
Targeted literature searches in the Medline and/or EMBASE databases using a combination of the 
disease names were conducted to identify the required data on correlations between the modelled 
diseases. Wherever possible, data on the incidence and prevalence of one disease with and without 
the other diseases was obtained. Further details on the correlations 2), 4) and 5) can be found in 
Youn (2016) [1].
Correlation between Heart disease and Alzheimers disease
Systematic searches for literature reporting the prevalence of AD and other co-existing conditions 
and the outcomes of intervention for patients with AD and other relevant conditions were 
conducted within the Medline and EMBASE databases. However, very few papers that could provide 
numerical data for populating the model were identified. 
A small number of studies that discussed empirical data on the effect of one disease on another 
were identified. As Maslow [2] noted, studies mainly listed common co-existing conditions that were 
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3present in their study population only, or intentionally excluded people with AD who have other co-
morbidities as the effect of other diseases could confound the effect of AD. Studies focussing on 
heart disease reported similar results. 
Correlation of prevalence
The prevalence of HD among AD patients was considered higher than that of HD within an age- and 
gender-matched general population.  A number of studies have found that AD often co-exists with 
vascular conditions such as hypertension, hyper-cholesterolaemia, and diabetes mellitus [2-6]. 
For instance, the US National Center for Health Statistics survey found that 82% of people in assisted 
living facilities where help is provided for daily activities such as bathing and dressing had one or 
more of dementia, hypertension, and heart disease (Figure S2.1) [7]. 42% of the residents had 
Alzheimers disease or other forms of dementia and 34% had heart disease. 14% of people had both 
dementia and heart disease and 9% of them had all three of the diseases. However, as this survey 
was conducted in assisted living centres, the survey respondents were likely to be older than other 
study populations. 
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4Figure S2.1. Co-morbidities of residents in assisted living facilities
Source: The National Center for Health Statistics, 2010 [7]
In order to incorporate the linkages between AD and HD, those with and without HD had different 
prevalence of AD: the total proportion of people who have AD was divided into the proportion of AD 
patients among people with heart disease and the proportion among people without HD. 
For each age and sex group, the total prevalence of AD, , can be seen as a weighted 
average of two conditional probabilities  and  as follows; 
         
[Eq. 1]
where AD and HD are binary variables taking the value of one when the disease is present and zero 
otherwise. Therefore,   and  are the prevalence of AD and HD, respectively. 
 denotes the probability of having AD conditional on the presence of HD, or the 
prevalence of AD among those with HD, and  the prevalence of HD among those 
with AD. 
In the same way, the total prevalence of heart disease can be calculated as:
        
[Eq. 2]
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5Eq. 2 expresses the total prevalence of HD in terms of  and  
using the value of AD prevalence, . Regardless of which equation to use, the split should 
be the same as  and  represent the same coloured area in 
Figure S2.2 although the actual figures of the conditional probabilities differ depending on which 
disease status is assumed to be known. 
Figure S2.2. Prevalence linkage between AD and heart disease
However, Eq. 2 could not be used as the total prevalence of heart disease had to be partitioned 
among the cardiac events included in the model and data required for using Eq. 2 were not available 
from the literature searches.  Hence, the prevalence of AD was divided into the prevalence of AD for 
people with and without HD using Eq. 1.
Using Bayes theorem,  in Eq. 1 was calculated as 
  [Eq. 3]. The relationship in Eq. 1 was used to 
calculate .  The following sections describe the methodology and report the 
calculation results. 
Calculation and calibration of the prevalence of Alzheimers disease among heart disease patients
The prevalence of AD among people with HD, , was calculated by combining the 
results on  and  using Eq. 3. Subsequently, the prevalence of AD 
among people without HD, ,  was also estimated using Eq. 1. 
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6The resulting prevalence of AD divided into  and  is shown 
in Table S2.1. These values were used in the linked model as the prevalence of AD in relation to the 
presence of heart disease. The ratio   varied with age group and sex as the prevalence 
of individual diseases,  and , differ between age and sex. 
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7Table S2.1. Prevalence of AD divided into the prevalence for people with HD and that for people 
without HD (before calibration)
Prevalence of AD
 P	ople with HD H People without HD  Ratio 4H5I+
Age Men Women Men Women Men Women
<65 0 0 0 0 NA NA
65-69 0.018267 0.044718 0.006785 0.005929 2.69 7.54
70-74 0.036962 0.05099 0.015618 0.009068 2.37 5.62
75-79 0.051255 0.091056 0.032751 0.034654 1.57 2.63
80-84 0.095646 0.180764 0.058681 0.068831 1.63 2.63
85+ 0.196727 0.363585 0.108037 0.132586 1.82 2.74
The prevalence of AD before and after applying the correlations were compared using the values 
sampled at the model entry in order to see whether the estimation method used for splitting 
prevalence produced similar results. The total prevalence of AD and the prevalence for people with 
and without HD are compared in Table S2.2. The prevalence values of AD with and without HD were 
combined for comparison with the total AD prevalence before splitting using 100,000 simulated 
individuals for each age group (in order to have enough numbers of simulated individuals in each age 
group). The absolute percentage differences ranged from 0.23% to 5.09% between the total 
population values and the split values of prevalence.  The percentage difference was the largest for 
female population aged 70-74 years. The differences could be due to the use of the single estimate 
of  in Eq. 3 for all age groups and sex, which fails to reflect variation among 
different populations in the estimation equation.  
Although the differences could be considered small, the prevalence of AD split for people with and 
without HD was calibrated to match the total prevalence. Calibration was performed in order to 
start the model with the same population with respect to the total prevalence of AD. Based on the 
total prevalence values, age- and sex-specific calibration multipliers were applied to the prevalence 
values for people with and without HD. These were calculated as the total prevalence divided by the 
combined prevalence using split values. The calibrated prevalence after these multipliers were 
applied was used in all models for this paper where AD and heart disease were correlated. 
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8Table S2.2. Comparison of simulated proportions of people with Alzheimers disease (AD): between 
when the total prevalence of AD was used and when the prevalence of AD split into HD and non-HD 
groups was used 
Total prevalence of 
AD (before splitting)
Combined 
prevalence of AD 
using split 
prevalence values*
% Difference 
(compared with the 
total prevalence AD)
Age Men Women Men Women Men Women
<65 0 0 0 0 0 0
65-69 0.0101 0.0108 0.0098 0.0104 -3.01% -3.98%
70-74 0.0223 0.0158 0.0232 0.0166 3.88% 5.09%
75-79 0.0403 0.0511 0.0387 0.0503 -3.94% -1.52%
80-84 0.0734 0.1015 0.0732 0.1020 -0.38% 0.44%
85+ 0.1411 0.1980 0.1451 0.1985 2.79% 0.23%
*Based on the results of 100,000 simulated individuals for each age group. 
In order to examine the effect of the calibration at the population level, the numbers of people with 
AD across all age groups in the models before and after calibration were compared in Table S2.3 
when 200,000 individuals aged 65 years and over were simulated for each model (the age 
distribution for people aged 65 and over was adapted from the ONS mid-2012 UK population 
estimates). The total numbers of people with AD among 200,000 simulated individuals from models 
with and without calibrated prevalence values were compared with that from the model where 
heart disease and AD were independently linked. The calibration reduced the difference between 
when the total AD prevalence was applied and when the split prevalence values were used from 
0.50% to 0.24% for male population and from 1.89% to 1.18% for females. 
There still existed differences in the number of people with AD after calibration due to Monte Carlo 
sampling error. Perfect calibration would have been possible if the calibration factors were 
calculated using the model results with the infinite number of runs for each age and sex group. In 
addition, if the infinite number of individuals were simulated in the perfectly calibrated model and 
the independently linked model for figures in Table S2.3, the differences would have been 
eliminated. 
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9Table S2.3. Number of individuals with Alzheimers disease (AD) before and after calibration 
compared with when total prevalence without correlations was applied
Number with AD when 
Total AD prevalence was 
used**
Number with AD when split prevalence values were used* 
(difference 
 %))
Men Women Men Women Men Women
Before calibration After calibration
3378 6292
3395
(+17; +0.50%)
6411
(+119; 1.89%)
3386
(+8; 0.24%)
6366
(+74; +1.18%)
*Among 200,000 simulated individuals aged 65 years and older; **Results from the model where 
heart disease and AD were linked with independence between diseases assumed. 
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Correlation between Heart disease and Osteoporosis 
The model in this study focussed specifically on correlations regarding hip fracture, and MI and 
stroke as these events are associated with the highest costs and utility effects. This section describes 
the correlation between hip fracture and a history of MI. Similar calculation was performed for the 
correlation between the risk of stroke and a history of hip fracture. 
Incidence of hip fracture and prevalent cardiovascular disease
Fracture risks are influenced by the presence of CVD.  In a study by Gerber and colleagues [8], MI 
was associated with higher risk of all types of osteoporotic fracture. Excess fracture risks after MI 
were found with the overall adjusted hazard ratio (HR) of 1.32 (95% CI 1.12-1.56) across all anatomic 
sites. Trends of the fracture incidence rates for three time-periods (1979-1989; 1990-1999; 2000-
2006) were tested and an increase in fracture rates over time was found among MI patients. An HR 
of 1.66 for both men and women for hip fracture was used in the model, which was for the most 
recent time period (2000-2006). Data reported in Gerber et al. [8] was used in the model as this 
study was based on a large sample size and similar ethnic group to that of the UK, and provided 
relatively recent data in the format suitable to be applied to the time-to-event distributions used in 
the model.  Only a transient increase of fracture risks after MI was identified in the study. In the 
Gerber et al. (2011) study, as the mean follow-up time was only 4 years and the association between 
and MI and 5-year risk of osteoporotic fracture was reported, HR was applied for five years after MI. 
The incidence of hip fracture was split between that for those with MI and that for those without. 
Using the prevalence estimates of MI used to populate the individual heart disease model, the total 
incidence of hip fracture was split between the incidence of hip fracture for patient who had an MI 
within 5 years and that for patients who did not have MI for the last 5 years. These were reported in 
Table S2.4 for those on no treatment (A) and on drug treatment for osteoporosis (B) where an RR of 
72% for hip fracture was applied [9]. Due to the low prevalence of MI among younger age groups, 
the baseline incidence for those without MI was similar to the total incidence including both groups 
with and without MI. 
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Table S2.4. Hip fracture incidence split between rates for those with MI and without MI
A. Hip fracture incidence with and without MI  No drug treatment
 Total incidence of hip 
fracture
Baseline rate r (without 
MI)
Rate for patients with MI
Age Men Women Men Women Men Women
45-50 0.00030 0.00020 0.00030 0.00020 0.00049 0.00033
50-55 0.00030 0.00020 0.00030 0.00020 0.00049 0.00033
55-60 0.00070 0.00050 0.00067 0.00049 0.00112 0.00082
60-65 0.00030 0.00080 0.00029 0.00079 0.00048 0.00131
65-70 0.00080 0.00130 0.00073 0.00127 0.00121 0.00211
70-75 0.00110 0.00210 0.00100 0.00206 0.00167 0.00341
75-80 0.00200 0.00420 0.00180 0.00396 0.00299 0.00658
80-85 0.0068 0.0097 0.00613 0.00915 0.01017 0.01519
85+ 0.0099 0.0217 0.00892 0.02047 0.01481 0.03398
B. Hip fracture incidence with and without MI  For individuals on drug treatment for 
osteoporosis
 Total incidence of hip 
fracture  on drug 
treatment
Baseline rate r (without 
MI)
Rate for patients with MI
Age Men Women Men Women Men Women
45-50 0.00025 0.00018 0.00025 0.00017 0.00041 0.00029
50-55 0.00024 0.00017 0.00024 0.00017 0.00040 0.00028
55-60 0.00050 0.00033 0.00048 0.00032 0.00080 0.00054
60-65 0.00020 0.00055 0.00019 0.00054 0.00032 0.00090
65-70 0.00060 0.00092 0.00054 0.00090 0.00090 0.00149
70-75 0.00081 0.00150 0.00074 0.00147 0.00123 0.00244
75-80 0.00145 0.00303 0.00131 0.00286 0.00217 0.00475
80-85 0.00490 0.00695 0.00442 0.00656 0.00733 0.01088
85+ 0.00713 0.01557 0.00643 0.01469 0.01067 0.02439
The incidence rates of hip fracture with and without a recent MI reported in Table S2.4 were used as 
the baseline event rates for hip fracture for the first 5 year period after MI. The relative risks 
associated with factors that can influence the event rates, such as low BMD and previous fracture, 
were applied onto these baseline rates. When sampling time to next hip fracture, these baseline 
incidence rates of hip fracture were updated when the sampled time to event was longer than the 
time before a change in age band, or the time left to a change in the drug efficacy due to the 
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treatment fall time after discontinuation. Hence, all three time intervals for which different event 
rates are applied  time to 5 years after MI, time to next age band, and time to next efficacy change 
due to the fall time of treatment effect  were continuously compared with the sampled time to 
event (TTE) value. When the sampled TTE value is longer than any of the three, the baseline 
incidence rates were changed accordingly and TTE was resampled. 
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2Appendix 3. Parameter estimates and data sources
Event Rates 
This section describes the event rates used for the base-case model only for HD due to the addition 
of PAD and updated parameters. Parameter estimates used in the AD and osteoporosis models were 
based on the data reported in the HTA reports [1, 2] and are detailed in Youn [3]. The data sources 
were identified from the six UK-based studies [4-9]. The most appropriate parameter estimates 
reported for similar populations and contexts in the six studies and their sources of data were used 
for the model in this research. UK-sourced data were used wherever possible, and age-dependent 
time-variant rates of transitions between health events were preferred.
All included HD disease states except PAD were split into two temporal categories  first year and 
subsequent years after the event  due to the difference in the rates for transitions to other events, 
costs, and/or utility weights between the first year of the event and thereafter.  Various sources for 
cardiac death rates were used dependent on the from state of the transition. The rate of transition 
to cardiac death varied with the age group and the temporal period (first year or subsequent years 
after the event), and time to cardiac death was sampled from an exponential distribution, the 
parameter of which produced the appropriate rate. 
The event rates used in the model are summarised in the next sections by the origin of transitions, 
with each section followed by a summary table of the estimates. In addition, rates of transitions to 
fatal stroke and PAD were described in separate sections as they applied regardless of the origin of 
transitions. 
Transitions from event-free state (at model initiation)
Event rates differed depending on whether an individual is on primary or secondary prevention 
interventions, or is untreated. Rates of transitions from the event-free state are summarised in Table 
S3.1. 
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3Table S3.1. Baseline annual rates of transition from event-free state
Baseline rates for individuals not receiving statin treatment
From To Estimates Sources
Event free MI Rate for men = 0.01624; Rate for 
women = 0.01123
WOSCOPS 
(Shepherd et al. 
1995 [10]) and 
Framingham 
studies 
(DAgostino et al. 
2008 [11])
Stroke Exponential mean of Exp(9.218 + (-
0.064)*age at event + (-
0.176)*gender) for time to event 
distribution . Then, the 
prob of stroke being fatal applied. 
P(fatal stroke)=e^xb/[1+e^xb] where 
xb= -4.874 + 0.043*age  
0.074*gender.  
Anglo-
Scandinavian 
Cardiac Outcomes 
Trial (ASCOT) trial 
results [8]
Angina Rate = 0.0027 per patient-year. ASCOT-LLA data 
[12] 
Revascularisation For only primary and secondary 
prevention populations, 
Exponential mean of Exp(5.250 + (-
0.013)*age at event + 
(0.479)*gender) for time to event 
distribution . 
Otherwise, the national average rate 
of revascularisation was used. 
ASCOT trial [8]
National Audit of 
PCI [13]
PAD Rate= 0.021149= the incidence of 
PAD with intermittent claudication.
Edinburgh Artery 
Study [14]
CVD death For individuals not receiving any 
interventions, 
Males (females): 45-54 years 
0.000639 (0.000178); 55-64 years 
0.001711 (0.000573); 65-74 years 
0.004275 (0.001994); 75-84 years 
0.013182 (0.008621); 85 years and 
over 0.040947 (0.035576).
For only primary and secondary 
prevention populations, 
Exponential mean of Exp(6.576 + (-
0.035)*age at event + 
(0.437)*gender) for time to event 
distribution .
Mortality 
Statistics: Deaths 
registered in 2012 
[15]
ASCOT trial [8]
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Table S3.2. Baseline annual rates of transitions from myocardial infarction
Baseline rates for individuals not receiving statin treatment
From To Estimate Sources
MI MI For age groups 1-5: First 
(subsequent) year(s) rates: 
0.13697 (0.01633),  
0.12239 (0.01806), 0.10747 
(0.01867), 0.09146 (0.0180), 
0.07375 (0.01613).
NICE TA94 Table 
52 [16]; 
Nottingham Heart 
Attack Register 
(NHAR) [17].
Stroke For age groups 1-5: First 
(subsequent) year(s) rates: 
Group 1 (< 55): 0.00150 (0.0004),  
Group 2 (55-65): 0.00321 (0.00100), 
Group 3 (65-75): 0.00682 (0.00220), 
Group 4 (75-85): 0.01420 (0.00471), 
Group 5 (> 85): 0.02819 (0.00914).
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR); 
Angina Exponential rate =  0.05975 Ara et al. 2009. 
Table 8 [9]; Fox et 
al. 2005 [18]
Revascularisation First year rate = 0.504347 TNT trial
[6]
PAD Rate= 0.021149= the incidence of 
PAD with intermittent claudication.
Edinburgh Artery 
Study (Leng et al. 
1996)
CVD death For age groups 1-5: First 
(subsequent) year(s) rates: 
Group 1 (< 55): 0.01755 (0.00541),  
Group 2 (55-65): 0.03387 (0.00955), 
Group 3 (65-75): 0.06465 (0.01603), 
Group 4 (75-85): 0.12059 (0.02482), 
Group 5 (> 85): 0.21791 (0.03615).
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR) 
[17].
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Table S3.3. Baseline annual rates of transitions from Stroke
Baseline rates for individuals not receiving statin treatment
From To Estimate Sources
Stroke MI Rates by age group: 
Group 1 (< 55): 0.00160,
Group 2 (55-65): 0.00310,
Group 3 (65-75): 0.00552,
Group 4 (75-85): 0.00803,
Group 5 (> 85): 0.01045.
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR) 
[17].
Stroke
(Stroke 
recurrence)
Baseline rates for 0-1, 1-5, 5-10 
years for individuals aged <65:
0-1 year rate= 0.06401 (mean = 
15.6237); 1-5 year rate= 0.02694; 5-
10 year rate= 0.01887.
Then, probability of stroke being 
fatal= e^xb/[1+e^xb], where
xb= -4.874 + 0.043*age  
0.074*gender, was applied. 
Mohan et al. 2009 
[19]  Stroke 
recurrence; ASCOT 
trial [8]
Angina Rate = 0.0027 Assumed the same 
as the rate of 
transition from 
event free to 
angina state (NICE 
TA 94 Table 52) 
Revascularisation Rate= 0.01056 TNT trial [6]
PAD Rate= 0.021149= the incidence of 
PAD with intermittent claudication.
Edinburgh Artery 
Study [14]
CVD death For age groups 1-5: First 
(subsequent) year(s) rates: 
Group 1 (< 55): 0.00924 (0.00421),  
Group 2 (55-65): 0.02245 (0.00985), 
Group 3 (65-75): 0.05340 (0.02102), 
Group 4 (75-85): 0.12466 (0.04207), 
Group 5 (> 85): 0.27839 (0.07796).
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR) 
[17]
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If the reported data did not explicitly state that the event probabilities were for non-fatal stroke only, 
then a proportion of the patients who experience a stroke was assumed to die due to the stroke. 
The proportion of fatal stroke among all stroke events was estimated using the logistic regression 
equation reported in the ASCOT trial results [8] with an exception of transitions from 
revascularisation state where a 50% probability of stroke being fatal was assumed as in Ara et al. 
(2009). Thus, the transitions to stroke from event free, stroke, angina and revascularisation states 
included a subset of patients having a fatal event and subsequently moving to cardiac death state.
ﬀﬁﬂﬃtions from Angina
Rates of transitions from angina are given in Table S3.4. Individuals were assumed to have stable 
angina first and then progress to unstable angina, which requires more intense medical treatments. 
Once unstable angina was developed, it was assumed that patients could not improve to stable 
angina. 
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Baseline rates for individuals not receiving statin treatment
From To Estimates Sources
Angina MI 1) From Stable angina: Rate = 0.01520;
2) Unstable angina
5%, 4.9%, 4.7%, 4.3% from 1st year event.
3.5%, 6.3%, 11.2%, 18.5% from subsequent 
yrs event for those aged <55, 55-65, 65-75, 
75-85 yrs, respectively. 
Juul-Moller, 
Edvardsson [20]; 
Ara, Pandor [9], 
Table 8; Gray and 
Hampton [17]; 
Stroke 1) From Stable angina: 
Rate = 0.00791; Then, the prob of stroke 
being fatal applied, probability = 
e^xb/[1+e^xb], where xb= -4.874 + 
0.043*age  0.074*gender. 
2) From Unstable angina: For age groups of 
<65, <75, <85, >85 years,
[1st year rate] To non-fatal stroke: 0.2%, 
0.5%, 1%, 2%; To fatal stroke: 2.6%, 4.3%, 
7%, 10.3%; 
[subsequent yrs rate] To non-fatal stroke: 
0.1%, 0.1%, 0.3%, 0.7%;  Fatal stroke: 
0.4%, 0.5%, 0.6%, 0.7%.
1) Juul-Moller, 
Edvardsson [20]; 
NICE [16]; Lindgren, 
Buxton [8]
2) Ara et al. 2009 
(HTA) Table 8.; 
Gray and Hampton 
[17]
Angina 
(unstable)
Annual probability from stable angina to 
unstable angina: 
Group 1 (< 55): 0.0013,
Group 2 (55-65): 0.0029,
Group 3 (65-75): 0.0060,
Group 4 (75-85): 0.0091, 
Group 5 (> 85): 0.0122. 
NICE TA 94: Table 
52. 
Revascularisat
ion
Rate=0.00269 Assumed the same 
as the minimum 
revascularisation 
rate from PAD state. 
(Leng et al. 1996)
PAD Rate= 0.021149= the incidence of PAD with 
intermittent claudication.
Edinburgh Artery 
Study (Leng et al. 
1996)
CVD death 1) If no history of angina= 
Group 1 (< 55): 0.009, 
Group 2 (55-65): 0.0035, 
Group 3 (65-75): 0.007, 
Group 4 (75-85): 0.007, 
Group 5 (> 85): 0.007.  
2) From unstable angina = (CHD and CVD 
death rates combined for 1st and 
subsequent years.
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR).
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Table S3.5. Baseline annual rates of transitions from revascularisation
Individuals not receiving statin treatment
From State To State Estimate Sources
Revascularisation MI Rate= 0.03874 Fox, Poole-Wilson 
[18]; Ara et al. 
(2009) [9]
Stroke Rate=0.002 with 50% of stroke 
being assumed to be fatal. 
Henderson, 
Pocock [21]; Ara 
et al. (2009) [9]
Angina Rate = 0.032523 Henderson et al. 
(2003); Ara et al. 
(2009) [9]
Revascularisation First-year rate  of having a 2nd 
revascularisation= 0.14491
TNT trial [6] 
PAD Rate= 0.021149= the incidence of 
PAD with intermittent claudication.
Edinburgh Artery 
Study [14]
CVD death Rate = 0.005785 RITA-2 trial [21]
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Table S3.6. Baseline rates of transitions from peripheral arterial disease
Baseline rates for individuals not receiving statin treatment
From To Estimate Sources
PAD MI Rate = 0.01711 Edinburgh Artery 
Study [14]
Stroke Rate= 0.01408 Edinburgh Artery 
Study [14]
Angina Rate= 0.02019 Edinburgh Artery 
Study [14]
Revascularisation Rate=0.00269 Edinburgh Artery 
Study [14]
PAD Rate=0 Assumed
CVD death Exponential mean of Exp(6.576 + (-
0.035)*age at event + 
(0.437)*gender) for time to event 
distribution .
The same rate as 
the transition 
from event free 
to CVD death: 
ASCOT trial [8]
Transitions to PAD
The incidence of PAD reported in the Edinburgh Artery Study was used for the estimation of 
transition rates to PAD. The incidence of symptomatic PAD (i.e. with intermittent claudication, IC) in 
general population aged 55 and over was used for all transitions to PAD event due to the lack of 
published evidence [14]. Age dependent incidence was not included as it was not statistically 
significant in the Edinburgh Artery Study [14]. However, there was some evidence of an increase 
with age in earlier longitudinal studies [22, 23].  
Among patients with PAD, approximately 20% progress to develop severe symptoms with critical 
limb ischaemia (CLI) over a 5-year period and 1-2% undergo amputation over a lifetime [24]. In the 
model, 20% of people with IC were randomly sampled to develop CLI at the time of developing PAD 
for simplicity, to whom higher costs and lower utility weights were applied. 
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Effectiveness of statin treatments
Statin interventions was assumed to reduce the risks of coronary events (MI, angina, and fatal CHD 
events) and stroke. The model assumes that a proportion of individuals entering the model are 
receiving a statin intervention for primary and secondary prevention of CVD events. The relative 
risks (RRs) of events associated with statin use were applied to the baseline risks converted from the 
event rates reported in Tables S3.1-S3.6, and are shown in Table S3.7.  
Table S3.7. Relative risks associated with statin use compared with placebo
Transitions to Relative Risk Source
MI 0.656 Ward et al. (2006) [4]
Non fatal stroke 0.754 Ara et al. (2009): Simvastatin 
40mg/day
Fatal stroke (from Angina 
state)
0.876 Ara et al. (2009): Simvastatin 
40mg/day
Stable Angina (from event free 
state)
0.59 Ward et al. (2006) [4]
To Fatal CHD event (CVD 
death)
0.74 Ward et al. (2006) [4]
Non CVD death (from event 
free state)
0.656 Ward et al. (2006) [4]
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Non-disease mortality
Non-cardiac mortality rates used to construct distribution profiles for time to non-disease death 
were calculated by subtracting cardiac mortality rates from the all-cause death probability profiles. 
Cardiac mortality rates were estimated by combining the rates reported for heart disease (ICD-10 
code I00-I52) and stroke (I64) using data obtained from the Mortality Statistics: Deaths registered in 
2012 [15]. Cardiac mortality rates used to calculate the non-disease mortality are shown in Table 
S3.8. These were the same rates used for transitions to cardiac death from event-free state.
Figure S3.1 shows distributions for time to non-cardiac death for a few selected age groups. As the 
cardiac death rates were assumed constant across the 10-year age bands whilst the all-cause 
mortality rates were specified at every age  between 45 and 100 years, the probability profiles 
created were not smooth, but had a few stepped decreases at the age cut off values. 
Table S3.8. Cardiac death rates used to estimate non-cardiac mortality rates*
Age group
Sex 45-54 55-64 65-74 75-84 85 and 
over
Male 0.000639 0.001711 0.004275 0.013182 0.040947
Female 0.000178 0.000573 0.001994 0.008621 0.035576
*Adapted from Table 8 in Deaths registered in England and Wales, 2012 [15]
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Figure S3.1. Illustration of distributions for time to non-cardiac death
Male aged 45 years Male aged 55 years
Male 65 years Male 75 years
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Costs
Table S3.9. Cost estimates used in the base-case model
Event Data within 
source
Price year Estimates [25]
(2011/2012 price)
Original Source
MI - 1st year £./996 2007  £  4,519.10 Ara et al. (2009) 
estimated using 
British National 
Formulary (2008) 
[26]
MI - subsequent 
year
£171 2004  £  214.89 NICE TA 94 (GP 
contacts + 
medication costs)
Stroke - 1st year £8,066 2007  £ 9,121.88 Ward, Lloyd-Jones 
[4]
Stroke - 
subsequent yr
£2,266 2007  £ 2,562.63 Ward, Lloyd-Jones 
[4]
Stable angina £171 2004  £ 214.89 NICE TA 94 (GP 
contacts + 
medication costs)
Documented 
angina
 £     587.07 2005  £ 713.94 Taylor et al. (2009)
Revascularisation 
- 1st yr
 £  5,857 2007  £ 6,623.71 Taylor et al. (2009); 
HRG
PAD (IC) £180 2009-
2010
£189.31 Kearns, Michaels 
[27]
PAD (CLI) £624 2009-
2010
£656.29 Kearns, Michaels 
[27]; National 
Clinical Guideline 
Centre [24]
Statin treatment £144.12 2014 £144.12 British National 
Formulary (2014); 
Estimated using the 
method by Ward et 
al. (2006)
Baseline utility values by age and gender in the UK general population were estimated from a 
statistical model reported in Ara and Brazier [28].
The utility values associated with the health states included in the model were obtained from NICE 
TA94 and the HTA report by Ara et al. (2009). Table S3.10 describes the original sources of these 
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values. All the utilities were estimated using the EQ-5D, and were assumed to be multiplicative. 
Utility multiplier values were assumed to increase by 10% after the first year of the event as 
assumed in Ara et al. (2009). It was assumed that the history of revascularisation procedure did not 
affect the utility level, and the utility decrement for stable angina was used for individuals with 
history of angina. As a base-case, deterministic values for utility multipliers were used.
Alongside the current event, the history of the other health events was incorporated in the utility 
multiplier. For example, if a man aged 65 years who has just had a stroke has a history of MI, then 
the utility decrements for both stroke (first year multiplier for stroke: 0.629) and that for MI 
(subsequent-year multiplier: 0.836) were applied to the baseline utility (0.815); the utility weight for 
this person is thus 0.429 (i.e. 0.815*0.629*0.836). 
When more than one cardiac event occurs within one year, the first-year periods of those events 
overlap. For the time periods overlapping, utility multipliers associated with the events were applied 
multiplicatively. For instance, if an individual experiences an MI at time=2.3 years and subsequently 
a stroke at time=2.7 years, then for time between 2.3 and 2.7 years, only the utility multiplier for the 
first year of MI would be applied (0.760) whilst for time between 2.7 and 3.3 years, utility multipliers 
associated with both first-year MI and first-year stroke would be applied (0.760*0.629=0.478). In the 
same way, for time between 3.3 and 3.7 years, utilities associated with subsequent years of MI and 
first year of stroke are used (0.836*0.629=0.526) In the model for this paper, whenever individuals 
reach these time points, they are directed to the utility cut off point event in order to update 
variables related to utility multiplier. 
Table S3.10. Utility multipliers by health state 
State First year - 
Mean (S.E.)
Subsequent years - Original Sources
MI 0.760 (0.018) 0.836 (10% increase) Goodacre, Nicholl [29]
Stroke 0.629 (0.04) 0.692 (10% increase) Tengs and Lin [30]
(Stable) angina 0.808 0.889 (10% increase) Melsop, Boothroyd [31]
Unstable angina 0.77 0.847 (10% increase) Goodacre, Nicholl [29]
Revascularisation 0.78 0.858 (10% increase) Serruys, Unger [32]
PAD IC 0.70 0.70 Kearns, Michaels [27]
PAD CLI 0.35 0.35 [Kearns, Michaels [27]]
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2Appendix mparison of the single-disease models in this study with the published reference models
Study Model 
type 
(software)
Base-case 
Population
Intervent
ion
Compara
tor(s)
Outcomes Perspecti
ve
Time 
horizon0
price 
year
Health 
events 
included 
(e.g. Markov 
health 
states)
Stratified 
results 
(Y12034)
Base-case 
I567
Parameters driving 
I567
Heart disease (HD)
HD single-
disease 
model in 
this paper
Discrete 
event 
simulation 
(Simul8)
General 
population 
aged 45 
years and 
over
Statins No 
statins
QALYs NHS Lifetime MI, stable 
angina, 
unstable 
angina, 
stroke, 
revascularisa
tion, PAD, 
CVD death, 
and non-
CVD death
Yes  Base-
case reported 
for the total 
population; 
and by age 
and gender, 
by prevention 
type 
1) Secondary 
prevention - 
£1.5k  
4.0k/QALY 
vary by age 
and gender
2) Primary 
prevention - 
£2.2k-2.8k 
varied by age 
and gender
Reduced cost of 
statins (updated to 
2012 values); 
Population age and 
sex distribution at 
model entry;
Added event of PAD 
could lower ICERs 
compared to the 
results from Ward 
et al. (2006) 
HD 
reference 
model by 
W89:
1
t al. 
(2006) [1]
Markov 
model
A 
population 
with CHD 
or at 
increased 
risk of CHD 
events 
(annual 
CHD risk of 
0.5%-3%)
Statins
as a 
group
No 
statins
QALYs NHS Lifetime/
2004
Discount 
rates of 
6% for 
costs and 
1.5% for 
health 
benefits
MI, stable 
angina, 
unstable 
angina, CHD 
death, TIA, 
stroke, and 
CVD death 
or non-CVD 
death
Yes  
Base-case 
reported by 
prevention 
level, age and 
sex, and 
predicted 
annual CHD 
risk levels
Multiple base-
case values
1) Secondary 
prevention - 
£10k-£17k 
/QALY
2) Primary 
prevention  
at annual CHD 
risk of 3%, 
£10k-37k 
/QALY for 
men and 
£14k-48k 
/QALY for 
women
Results were most 
sensitive to the cost 
of
statins, discount 
rates and the 
timeframe of the 
model; Larger 
incremental costs 
than the model in 
this study;
ICERs sharply 
increased with age 
of the population
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3Alzheimers disease (AD)
AD model 
in this 
paper
Discrete 
event 
simulation 
(Simul8)
General 
population 
aged 45 
years and 
over
Donepezil 
and 
memanti
ne 
BSC QALYs NHS and 
PSS
Lifetime AD onset; 
diagnosis; 
pre-
institutionali
sation; 
institutionali
sation; and 
death
Yes  results 
reported for 
two age 
groups aged 
>45 and >65 
years
Donepezil and 
memantine 
therapy 
dominated 
BSC (cost 
saving £14 
with 0.001 
QALY gain)
The model results 
were generally 
comparable with 
those from Bond et 
al. (2012).
Incremental QALYs 
from the model for 
this study were 
smaller than those 
from Bond et al. 
(2012) as the 
general population 
was modelled with 
the added events of 
the onset and 
diagnosis of AD. 
AD 
reference 
model by 
Bond et al. 
(2012) [2]
Markov 
model 
(Microsoft 
Excel)
People 
with mild, 
moderate 
or severe 
AD
donepezil
, 
galantami
ne,
rivastigmi
ne, for 
mild-to-
moderate 
AD, and 
memanti
ne, for 
moderate
-to-
severe AD
BSC QALYs NHS and 
PSS 
20 years
/ 2009 
price
pre-
institutionali
sation; 
institutionali
sation; and 
death
Yes  by 
disease 
severity 
Donepezil for 
mild-to-
moderate AD 
dominated 
BSC; 
Memantime 
for moderate-
to-severe AD: 
£32.1K/ QALY 
(increC=£405; 
increQ 
=0.013)
Results sensitive to 
assumptions on 
discontinuation 
rates; Costs of 
institutionalisation 
Osteoporosis
O;<=>?>ro
sis model 
in this 
paper
Discrete 
event 
simulation 
(Simul8)
General 
population 
aged 45 
years and 
70mg 
alendron
ate taken 
once 
No 
alendron
ate 
treatmen
QALYs NHS and 
PSS
Lifetime Hip fracture; 
vertebral 
fracture, 
wrist 
Yes  by age 
and gender, 
BMD level, 
status of 
Alendronate  
dominated no 
treatment for 
75-year-old 
Age, BMD level and 
history of previous 
fracture altered the 
incremental costs 
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4over weekly t fracture; 
proximal 
humerus 
fracture; 
fracture-
related 
death; non-
fracture 
death
previous 
fracture
women with 
T-score of -3 
SDs and -2.5 
SDs with no 
previous 
fracture
and QALYs. 
However, 
regardless of the 
willingness-to-pay 
threshold per QALY, 
the alendronate is 
likely to be a cost-
effective option for 
fracture prevention.
Osteoporo
sis 
reference 
model by 
Stevenson 
et al. 
(2009) [3]
Patient-
level 
Markov 
model 
(Microsoft 
Excel)
Postmenop
ausal 
women 
aged 50 
years and 
over
Vitamin 
K; 
alendron
ate; 
risedrona
te; 
strontium
ranelate
No 
alendron
ate; next 
cost-
effective 
treatmen
t options
QALYs NHS and 
PSS
10 years 
(the 
results 
subseque
ntly 
adjusted 
to 
account 
for 
treatmen
t benefits 
beyond 
the initial 
10 years)
Hip fracture; 
vertebral 
fracture, 
wrist 
fracture; 
proximal 
humerus 
fracture; 
nursing 
home entry 
from hip 
fracture; 
breast 
cancer; and 
coronary 
heart 
disease; and 
non-fracture 
related 
death
Yes  by age, 
BMD level, 
and status of 
previous 
fracture
Alendronate  
dominated no 
treatment for 
75-year-old 
women with 
T-score of -3 
SDs with no 
previous 
fracture; 
@AB226/QALY 
for 75-year-
old women 
with T-score 
of -2.5 SDs. 
Age, fracture risks, 
BMD and history of 
previous fracture 
could alter the ICER 
estimates. 
Page 74 of 141
5References
[1] Ward S, Lloyd-Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. Statins for the Prevention 
of Coronary Events: The University of Sheffield; 2006.
[2] Bond M, Rogers G, Peters J, Anderson R, Hoyle M. The effectiveness and cost-effectiveness 
of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimers disease 
(review of TA111): a systematic review and economic model. Health Technology Assessment. 2012; 
16(21):469.
[3] Stevenson M, Lloyd-Jones M, Papaioannou D. Vitamin K to prevent fractures in older women: 
systematic review and economic evaluation. Health technology assessment (Winchester, England). 
2009; 13(45):iii-xi, 1-134.
Page 75 of 141
1Supplementary Appendices
Supplementary Material for: 
Modelling the economic impact of interventions for older populations 
with multimorbidity: a method of linking multiple single-disease 
models
Ji-Hee Youn, Matt D. Stevenson, Praveen Thokala, Katherine Payne and Maria Goddard
Corresponding author: 
Ji-Hee Youn, PhD, MSc, BA 
jihee.youn@manchester.ac.uk; 
Appendix 1. Justification for disease selection
Appendix 2. Incorporating correlations between diseases
Appendix 3. Parameter estimates and data sources
Appendix 4. Comparison of the single-disease models in this study with the published reference 
models
Appendix 5. Dealing with stochastic uncertainty around the results from the linked model
Appendix 6. Summary of the results from the individual disease models for comparison
Appendix 7. Hypothetical scenario with similar levels of QALY gains assumed for all three 
interventions
Appendix 8. Probabilistic sensitivity analysis of the correlated linked model results
Page 76 of 141
2Appendix aling with stochastic uncertainty around the results 
from the linked model
Background : Uncertainty around DES model outputs can be represented by both first-order 
uncertainty, defined as stochastic variability between simulated observations assuming identical 
parameter values, and second-order uncertainty, defined as uncertainty in the parameters of the 
economic model [1]. 
Aim: The degree of first order uncertainty in the linked model was examined in order to identify the 
appropriate number of simulated individuals to ensure stable model results.  Stability was defined as 
an adoption decision being robust with sufficiently small random errors.
Method: Incremental values were computed in comparison with no treatments for all three of the 
diseases (heart disease, Alzheimers disease and osteoporosis). The first-order uncertainty around 
the mean incremental cost and QALYs, incremental net monetary benefit (NMB) and cost per QALY 
gained (CPQ) was quantified for the results from the correlated linked model for the population aged 
45 years and older. 
The jackknife approach was used to estimate a confidence interval for the mean cost per QALY with 
a reduced level of bias associated with the classical estimation of non-linear statistics [2, 3]. The 
standard errors of the mean results were estimated having varied the numbers of simulated 
individuals ranging from 1,000 to 700,000.  The jackknife 95% confidence interval for the mean CPQ 
and the NMB results with more than 400,000 simulated individuals were derived using R 
programming language (R version 3.2.1, © The R Foundation) due to limited capacity of the 
spreadsheet software. Jackknifing execution time for the data from 700,000 simulated individuals 
was 4.69 hours on an Intel ® Core  i5 CPU 2.30 GHz processor with 4.00 GB of RAM (3.54 hours for 
600,000 data points). 
Results: Figure S5.1 shows that the incremental cost and QALYs stabilised when more than 200,000 
individuals were simulated. The standard errors of the mean NMB and CPQ started to stabilise after 
running more than 500,000 simulated individuals. The chosen number of individuals to simulate was 
700,000 for the base-case all-disease linked models (with and without correlations) in order to 
further reduce the variability of the results. 
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3Figure S5.1. First order uncertainty in relation to the number of patients simulated in the all-disease 
linked model with correlations (base-year population aged 45 years and over)
1) Incremental cost (compared with none of the three treatments)
Undiscounted Discounted
2) Incremental QALYs (compared with none of the treatments for the three diseases)
Undiscounted Discounted
3) Cost per QALYs (95% jackknife confidence interval)
Undiscounted Discounted
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44) Net monetary benefit (£20,000 threshold)
Undiscounted Discounted
Each figure includes error bars showing the standard error in the mean estimates of (incremental) cost and 
QALYs.
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2Appendix mary of the results from the individual disease models for comparison
1) 
Heart disease only model
2) 
AlzheimCDEs disease only model
3) 
Osteoporosis only model
4) 
Sum of 
incremental values 
across 1)-3)
Treatment No 
treatment
Incremental 
values (A)
Treatment No 
treatment
Incremental 
values (B)
Treatment No 
treatment
Incremental 
values (C)
FGHKFLHK(C)
Cost - 
Discounted
£ 8,091 £ 7,569 £ 522 £4,582 £4,596 -£ 14 £ 2,847 £ 2,947 -£ 100 £ 408
QALYs - 
Discounted
9.249 8.978 0.271 10.642 10.641 0.001 11.191 11.184 0.008 0.280
Cost £ 14,224 £ 13,197 £ 1,027 £8,845 £8,869 -£ 23 £ 6,151 £ 6,324 -£ 173 £ 831
QALYs 13.843 13.257 0.586 16.548 16.545 0.003 17.759 17.751 0.009 0.597
Life years 
lived
21.319 20.319 1.000 21.653 21.650 0.003 23.530 23.525 0.004 1.007
ICER  
Discounted 
£ 1,926 
/QALY
Dominating Dominating £ 1,458 /QALY
ICER £ 1,754 / 
QALY
Dominating Dominating £ 1,391 / QALY
HD: based on n=200,000; AD n=200,000; Osteoporosis n=400,000
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2Appendix scenario with similar levels of  gains 
assumed for all three interventions
In order to examine the effect of sampling error when all three treatments have a similar level of 
QALY gains, the scenarios in Table S7.1 were assumed: these are not meant to provide accurate 
evaluations of current treatments but to show that the results would have face validity when QALY 
gains are comparablMN Qor all three individual diseases, populations aged 65 years and older were 
simulated. Scenarios for larger QALY gains for AD and osteoporosis and reduced QALY gain for HD 
were explored. Table S7.1 shows the scenario assumptions applied to each of the three disease 
models in comparison with the base-case assumptions. 
Table S7.1. Comparison of scenario assumptions and base-case assumptions
Base-case assumptions Scenario assumptions
1. Heart disease model
Relative risks were assumed to be 0.656, 
0.754, 0.876, 0.59, 0.74, and 0.656 for MI, 
non-fatal stroke, fatal stroke, stable angina, 
fatal CHD, and non-cardiac death, 
respectively. 
Relative risks of 0.98 for statin treatment 
were assumed for all events. 
Utility values for MI, stroke and 
revascularisation were set to 0.76, 0.629, and 
0.78, respectively.
Utility values for MI, stroke, and 
revascularisation were reduced to 0.5.
2. Alzheimers disease model 
4% of monthly treatment discontinuation 
rate was assumed. 
Lifetime treatment: No treatment 
discontinuation was assumed
6 months duration of treatment effect was 
assumed.
Lifetime treatment effect was assumed.
Utility value for institutionalised individuals 
was 0.33.
Utility value for those institutionalised was 
reduced to 0.1
The average annual improvements in MMSE 
score were 2.48 for donepezil and 1.4 for 
memantine per year. 
Double treatment effect on MMSE score: 
the average improvements in MMSE score 
were set to 4.96 for donepezil and 2.8 for 
memantine per year. 
Some individuals are institutionalised at 
model entry, and some patients are 
institutionalised immediately after diagnosis.
No individuals start at the 
institutionalisation state at model entry, nor 
get institutionalised immediately after the 
diagnosis (i.e. No individuals move to the 
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3institutionalisation event from the diagnosis 
event with RSUo time passed.V
3. Osteoporosis model
Relative risks of fracture for alendronate 
treatment were set to 0.72, 0.58, and 0.82 
for hip, vertebral, and other fractures, 
respectively. 
Relative risks were assumed to be 0.33 for 
all fracture types. 
5 years of treatment duration was assumed. Lifetime treatment duration was assumed. 
Table S7.2 compares incremental outcomes from the three individual disease models with those for 
each of the individual treatments from the linked model where the diseases were assumed to be 
independent. Under the hypothetical scenarios, a comparable magnitude of QALY gains across all 
three individual disease models (Table S7.2 Column a) was achieved.  The margins of error around 
incremental costs and QALYs at 95% confidence level are shown in brackets. 
Table S7.2 reports results under the scenarios in Table S7.1, assuming the diseases were 
independent. When none of the treatments have much larger impact on QALYs gained the linked 
model produced similar results to those from the individual disease models. This shows the 
robustness of the adoption decision within the linked model for individual treatments.  
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4Table S7.2. Cost-effectiveness results under larger QALY gain scenarios for individual treatments 
from the individual disease models and the independently linked model
1. Heart disease
a. Individual heart 
disease model
b. Independently linked model (n=700,000)
Incremental values 
XYZ[\]^ of er[_[` 
All 
treatments
b_ cd
treZfgh^fi
Incremental 
values
DCost £ 683 (£ 66) £ 11,001 £ 10,201 £ 800
DQALYs 0.0539 (0.0179) 4.9232 4.8784 0.0448
TCost £ 913 (£ 94) £ 15,499 £ 14,380 £ 1,119
TQALYs 0.0875 (0.0267) 6.2589 6.1861 0.0728
ICER (disc.) £ 12,665 £ 17,878
ICER £ 10,433 £ 15,360
2. Alzheimers disease (AD)
a. Individual AD 
model
b. Independently linked model (n=700,000)
Incremental values 
(Margin of error) 
All 
treatments
No AD 
treatment*
Incremental 
values
DCost -£ 4,551 (£ 93) £ 11,001 £ 15,413 -£ 4,412
DQALYs 0.0508 (0.0020) 4.9232 4.8855 0.0377
TCost -£ 6,319 (£ 130) £ 15,499 £ 21,582 -£ 6,083
TQALYs 0.0688 (0.0028) 6.2589 6.2089 0.0500
ICER (disc.) Dominating Dominating
ICER Dominating Dominating
3. Osteoporosis
a. Individual 
osteoporosis 
model
b. Independently linked model (n=700,000)
Incremental values
(Margin of error) 
All 
treatments
No osteoporosis 
treatment*
Incremental 
values
DCost -£ 1,186 (£ 74) £ 11,001 £ 11,983 -£ 982
DQALYs 0.0545 (0.0128) 4.9232 4.8918 0.0314
TCost -£ 1,856 (£ 123) £ 15,499 £ 16,970 -£ 1,471
TQALYs 0.0900 (0.0204) 6.2589 6.2090 0.0499
ICER (disc.) Dominating Dominating 
ICER Dominating Dominating
 Based on n=200,000 for HD and AD models; and n=400,000 for osteoporosis model, as in the base-case;  Margin of error 
at 95% confidence level; *The other two default treatments were assumed to be available; D=discounted.
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5jkmp qul the individual disease models produce similar QALY gains vwxykzut any disease with a 
significantly larger i{|q}y~ yke i{|q}y z znte Carlo error for one disease on the incremental 
outcomes and cost-effectiveness of the other diseases can be much less influential. one of the 
margin of error estimates in Table S7. v 0.0020, and 0.0128 for HD, AD, and osteoporosis 
models, respectively) will have a significant effect that changes the +/- signs of the values on the 
incremental QALY results from the linked model (0.0448, 0.0377, and 0.0314 for HD, AD, and 
osteoporosis treatments, respectively).  Hence, when QALY gains are similar across all diseases, the 
results are less susceptible to sampling error from the other diseases. The base-case estimated very 
small QALY gains for AD and osteoporosis treatments which could fluctuate between positive and 
non-positive values due to the sampling error associated with the treatment for HD. In cases where 
QALY gains are similar, however, the proposed methods of linking individual disease models are 
likely to produce more accurate cost-effectiveness estimates for individual treatments. 
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2Appendix babilistic sensitivity analysis of the correlated linked 
model results
The correlated linked model for the three diseases (HD, AD and osteoporosŁ was built 
probabilistically to take account of the uncertainty around input parameter point estimates. This 
section provides probabilistic results in order to show the feasibility of probabilistic sensitivity 
analysis (PSA using the linked model described in this paper. 
A probability distribution was defined for selected input parameters. The selection of parametric 
distributions was based on the nature of the d or example, utilities were assumed beta-
distributed as the data were assumed to be bounded by zero and one. Wherever possible, 
probabilistic distributions reported in the original publications of the reference models [1-3] were 
used. Where this was not possible, the distribution was parameterised using estimates of the error 
around mean or assumed standard errors for the purpose of this feasibility run of PSA.  Table S8.1 
shows the PSA input parameters and their distributional properties. 
Table S8.1. Variables and distributions used in the probabilistic sensitivity analysis (PSA)
PSA Variable Point estimate* Distribution Distributional properties
 e
RR of statin treatment for 
MI
0.656 Lognormal Lognormal(logmean=-0.4219, 
logSE=0.0233)
RR of statin treatment for 
stroke
0.754 Lognormal Lognormal(logmean=-0.2826, 
logSE=0.0203)
Change in MMSE when using 
Donepezil 10mg 
1.24** Normal Normal(1.24, 0.22)
Change in MMSE when using 
Memantine 20mg
0.70** Normal Normal(0.70, 0.35)
Proportion of patients 
compliant to medication
0.75 Beta Beta(13.31, 4.44)
  hea te
Stable angina 0.808 Beta Beta(86.00, 20.44)
Unstable angina 0.77 Beta Beta(93.67, 27.98)
MI 0.76 Beta Beta(427.09, 134.87)
Stroke 0.628 Beta Beta(91.07, 53.94)
MMSE: 0-9 0.33 Beta Beta(36.59, 74.28)
MMSE: 10-14 0.49 Beta Beta(78.04, 81.22)
MMSE: 15-20 0.5 Beta Beta(856.27, 856.27)
MMSE: 21-25 0.64 Beta Beta(1137.19, 639.67)
MMSE: 26-30 0.69 Beta Beta(282.51, 126.92)
Institutionalised 0.33 Beta Assumed the same as the utility 
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3value for E:0-9
 ¡¢¤¡bral fracture  1st year 0.626 Beta Beta(14.03, 8.38)
Vertebral fracture   
subsequent year
0.909 Beta Beta(6.61, 0.66)
Hip fracture   1st year 0.792 Beta Beta(12.26, 3.22)
Hip fracture  subsequent 
year
0.813 Beta Beta(11.55, 2.66)
¥¦§¨§
Cost of institutionalisation £2941 Normal Normal(2941, 108)
Cost of death from hip 
fracture
£9525.86 Gamma Gamma(scale=67.19, 
shape=141.78)***
MMSE: mini mental score examination; *mean values used in base-case analysis; **6month 
estimate; ***calculated from assumed standard error of 800.
The probabilistic model results are shown in Table S8.2 based on 300 PSA runs in each of which 
700,000 individuals were simulated. The mean cost and QALYs of the PSA results in Table S8.2 
showed comparable results with the base-deterministic results from the correlated linked model 
albeit not identical. All of the PSA samples in Figure S8.1 showed cost per QALY being lower than the 
threshold of £20,000 per QALY gained. 
Table S8.2. Comparison of probabilistic model results with the base-case deterministic results*
Deterministic results Probabilistic resultsAll-disease 
linked 
model with 
correlations
All three 
treatments 
assumed
None of 
the three 
treatments 
assumed
Incremental 
values
All three 
treatments 
assumed
None of 
the three 
treatments 
assumed
Incremental 
values
Mean cost £14,741 £13,894 £847 £14,392 £13,575 £816
Mean 
QALYs
8.962 8.725 0.236 8.972 8.731 0.241
ICER £3,583/QALY £3,391/QALY**
*Based on 300 PSA runs; each deterministic run is based on 700,000 simulated individuals; 
**Jackknife 95% C.I. £3,360-£3,423.
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4Figure S8.1. Probabilistic sensitivity analysis scatterplot of incremental costs and QALYs
                      *Based on 300 PSA runs
The results show that the adoption decision is robust when assuming the willingness-to-pay 
threshold o© ª«¬­000 per QALY gained. Each deterministic run of 700,000 individuals took 
approximately 15 minutes to run and hence, conducting 300 PSA runs for each intervention arm 
took 1.9 days of computing time (Intel CoreTM i7CPU 3.40GHz processor with 16GB RAM). Such time 
scales indicate it is feasible to conduct PSA using the multi-disease linked model. The probabilistic 
analysis of discrete event simulation model will become more achievable by using a computer with 
more processing power or parallel computing. The number of runs required would be affected by 
the homogeneity of the population studied. Hence, the use of a more narrowly defined population 
with specific characteristics and higher disease prevalence, than the general population adopted in 
the current analysis, would accelerate convergence due to higher number of disease events 
simulated and more homogeneous parameter values. 
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Figure 1. A schematic diagram of the linked disease model
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Figure 2. Discrete event simulation (DES½ ¾¿Àel with and without model linkagÁÂ
a. DES model ÃÄÅ a cohort model with fixed time cycles (Markov model)
i) DES model ii) Markov model
b. Single-disease DES models vs. a linked DES model
i) Two single-disease models for Disease A and Disease B ii) A linked DES model with Disease A and Disease B events merged
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ÆÇÈÈ y-axes of the diagrams show examples of variables defining the respective models and changes in their values over simulation time (x-axeÉÊË ÌÍÈobal parameters: 
variables that apply to all simulated individuals such as discount rates, unit cost of interventions and utility associated with health events; **Individual attributes: variables 
that reflect changes in individual characteristics over time such as age, a previous experience of disease events and utility multipliers relevant to the individual at specific 
event timÎÉË ÏÐÎÑÒÓÔÈ ÓÕÖting variable was added after combining all single-disease model variables in the linked model to indicate in which disease model the next event is 
scheduled to occur. 
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Figure 3. The structure of the individual disease models
a) Heart disease model*
×ØÙ Úyocardial infarction; PAD: peripheral artery disease; Revasc: revascularisation;
The heart disease model included MI, stroke, angina, revascularisation PAD and cardiac and non-
cardiac deaths as qualifying health events. Each non-fatal cardiac event except PAD (MI, angina, 
stroke and revascularisation) was divided into two temporal categories: first-year and subsequent 
years after the event.
b) Alzheimers disease model
Alzheimers disease: The onset and diagnosis of AD were added to the structure of the model by 
Bond et al. (2012) in order to model a general population.
c) Osteoporosis model*
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Osteoporosis model: Four fractures (hip, vertebral, wrist and proximal humerus) were included as 
osteoporotic fracture events. The events also included nursing home entry from hip fracture; death 
following fracture; and non-fracture related death (see Stevenson et al. 2009).
*The utility updates event was included in Figure 2a and 2c in order to reflect the differences in costs 
and utilities for the first year and subsequent years after each event. This event activated a transient 
utility state where a different utility value is applied when there is no actual disease event but there is a 
change in utilities and costs.  
Figure 4. Comparison of incremental costs and QALYs from the three individual disease models
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2Appendix fication for disease selection
The criteria used for selecting the diseases to be modelled in the case study are summarised in ÛÜÝ 1. 
Box 1. Criteria for selecting diseases to model
o Diseases with major cost implications: High costs to the UK NHS and Personal Social Services 
of treating/managing the diseases
o Diseases of the elderly: Diseases with significant mortality and morbidity burden for older 
population and diseases whose incidence is expected to increase as population ages.
o Establishing a balance between different disease areas in order to cover a spectrum of 
conditions.
o Diseases that are correlated with respect to their incidence/prevalence and thus are more 
likely to co-occur
o Whether there are sufficiently recent HTA reports undertaken for the disease in order that a 
peer-reviewed model could be replicated.
o Diseases of hard endpoints, rather than those being risk factors for other diseases 
themselves, such as diabetes and hypertension
Diseases with significant cost implications to the UK NHS and Personal Social Services (PSS) for an 
ageing population were considered for inclusion in the model. Diseases expected to become more 
prevalent as a population ages were given a priority. 
A balance between different disease areas was also considered as one of the criteria. Including 
diseases from one or two areas of diseases whose mechanisms are similar may be misleading in 
estimating the broad impact of population ageing on healthcare expenditure and the interactions 
between diseases. Among diseases of significant economic, mortality and morbidity burdens, a 
spectrum of diseases that affect different parts of the body were included. 
Diseases that are potentially correlated were considered for inclusion in the case study. Seemingly 
unrelated health conditions may co-occur in individuals as they often share common underlying risk 
factors (for further details, see Appendix 2). 
Page 98 of 141
3Þßàáâãßä ßisks are influenced by the presence of cardiovascular diseàåä æçèéêë  In a study that was a 
part of the Rochester Epidemiology Project, myocardial infarction æìíê îàå àååïciated with higher 
risk of all types of osteoporotic fracture [1]. Excess fracture risks afteß ìí îäre found with the 
overall adjusted hazard ratio æðñê ïò óëôõ æö÷ø CI 1.12-1.56) across all anatomic sites. 
Further, the prevalence of heart disease (HD) among Alzheimers disease (AD) patients was 
considered higher than that of HD within an age- and gender-matched general population.  A 
number of studies have found that AD often co-exists with vascular conditions such as hypertension, 
hyper-cholesterolaemia, and diabetes mellitus [2-6]. 
Osteoporosis and stroke share several risk factors, including age, smoking, low physical activity, and 
hypertension. Thus, low bone mineral density (BMD) and high stroke risk can be correlated. Studies 
have shown that low BMD or a history of fracture has an association with the incidence of stroke [7-
9]. Jørgensen et al. [9] reported that women with BMD values in the lowest quartile had a higher risk 
of stroke than women with BMD values in the highest quartile (odds ratio (OR)= 4.8), and a linear 
trend over the quartiles was statistically significant. The OR for stroke increased 1.9 per SD (0.13 
g/cm2) reduction in BMD. The association between low BMD and stroke in women remained 
significant when the analysis was adjusted for potential confounders. In men, however, no 
statistically significant difference in BMD between the stroke patients and their controls was found.  
The presence of recently published (or in press) NIHR HTA reports was considered as it was deemed 
as evidence of the importance of the disease to major stakeholders such as decision-makers in local 
government, policy-makers (including the National Institute for Health and Care Excellence (NICE)), 
health professionals, and the general public. Further, the model structures reported in the HTA 
reports were largely replicated. 
Diseases with hard endpoints were preferred to those which were surrogate risk factors for other 
diseases. It was believed that such diseases could be embedded as a risk factor, and the 
consequences of the diseases could be represented in the models of other diseases. 
Using the selection criteria, the three diseases with significant mortality and disability burdens for 
the elderly  heart disease (including stroke and MI), Alzheimers disease, and osteoporosis  were 
chosen for the case study.  
The most expensive disease category was cardiovascular disease.  Heart conditions, such as coronary 
heart disease (CHD) and MI, and stroke were selected for modelling as they account for the largest 
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4proportion of mortality and prevalent cases in cardiovascular disease among older individuals [10], 
and impose significant economic burden on the overall healthcare system [11]. 
Dementia was selected for modelling considering its cost, potential association with ùúûü ýþß
balance between the chosen diseases, and likely impact of population ageing. Amongst brain 
disorders, dementia was the most expensive category of spending [12], and affects older people in 
particular with the incidence positively correlated with age [13]. Only the most common form of 
dementia, Alzheimer  sease (AD)ü was modelled in this study as the currßý CE guidance and 
relevant model-based studies (including HTA reporý ) focussed on AD.
It was considered appropriate to include one or more musculoskeletal disorders due to the 
increasing prevalence and incidence with age. Amongst the musculoskeletal conditions, osteoporosis 
was deemed appropriate to include in the model due to its high cost.  Osteoarthritis (OA
)
 was not 
selected as previous models have been built for OAs at different anatomical sites such as knees, hips, 
and joints of hands, which make OA more difficult to include given the aim of this paper. 
Frthermore, the incidence of OA is difficult to estimate as the onset is not well-defined due to the 
discrepancy between the symptomatic OA and OA based on the radiological changes.  Rheumatoid 
arthriti  s) 	
   idered for inclusion as RA mainly affects people aged 65 years and older [14]. 
However, RA was not chosen for the modelling given that the cost of RA did not exceed that of OA 
and chronic obstructive pulmonary disease. 
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5Appendix 2. Incorporating correlations between diseases
The following correlations were incorporated in the proof-of-concept model.
1 Prevalence of AD for people with and without HD
2
Incidence of AD for people with and without HD
3 Incidence of hip fracture for people with and without a history of 
4
Stroke risks among people with and without a history of hip fracture
5 Incidence of AD with and without low  
AD=Alzheimer isease; HD= heart disease;  ﬀﬁdial infarction; ﬂﬃbone mineral density
This section describes only the correlations between the prevalence of HD and AD ((1 in above table 
and the incidence of osteoporotic fracture and the presence of HD ((3 n above ncorporated in the 
linked model and how these correlations were implemented. The correlation!
1
"5

#$%e selected 
due to the data availability. Different incidence and prevalence estimates were applied to two 
groups of people with and without the other underlying condition.  Similar calculation methods to 
those described in this section were applied to other correlations. 
Targeted literature searches in the $&'ine and/or E ASE databases using a combination of the 
disease names were conducted to identify the r$e*ired data on correlations between the modelled 
diseases. Wherever possible, data on the incidence and prevalence of one disease with and without 
the other diseases was obtained. +*rther details on the correlations 2

, 4

,-
&
5

d,- be found in 
Youn (2016) [15].
Correlation between Heart disease and Alzheimers disease
Systematic searches for literature reporting the prevalence of AD and other co-existing conditions 
and the outcomes of intervention for patients with AD and other relevant conditions were 
conducted within the Medline and EMBASE databases. However, very few papers that could provide 
numerical data for populating the model were identified. 
A small number of studies that discussed empirical data on the effect of one disease on another 
were identified. As Maslow [2] noted, studies mainly listed common co-existing conditions that were 
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6present in their study population only, or intentionally excluded people with AD who have other co-
morbidities as the effect of other diseases could confound the effect of AD. Studies focussing on 
heart disease reported similar results. 
Correlation of prevalence
The prevalence of HD among AD patients was considered higher than that of HD within an age- and 
gender-matched general population.  A number of studies have found that AD often co-exists with 
vascular conditions such as hypertension, hyper-cholesterolaemia, and diabetes mellitus [2-6]. 
For instance, the US National Center for Health Statistics survey found that 82% of people in assisted 
living facilities where help is provided for daily activities such as bathing and dressing had one or 
more of dementia, hypertension, and heart disease (Figure S2.1) [16]. 42% of the residents had 
Alzheimers disease or other forms of dementia and 34% had heart disease. 14% of people had both 
dementia and heart disease and 9% of them had all three of the diseases. However, as this survey 
was conducted in assisted living centres, the survey respondents were likely to be older than other 
study populations. 
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7Figure S2.1. Co-morbidities of residents in assisted living facilities
Source: The ./067nal Center for Health Statistics, 2010 [16]
In order to incorporate the linkages between AD and HD, those with and without HD had different 
prevalence of AD: the total proportion of people who have AD was divided into the proportion of AD 
patients among people with heart disease and the proportion among people without HD. 
For each age and sex group, the total prevalence of AD, , can be seen as a weighted 
average of two conditional probabilities  and  as follows; 
         
[Eq. 1]
where AD and HD are binary variables taking the value of one when the disease is present and zero 
otherwise. Therefore,   and  are the prevalence of AD and HD, respectively. 
 denotes the probability of having AD conditional on the presence of HD, or the 
prevalence of AD among those with HD, and  the prevalence of HD among those 
with AD. 
In the same way, the total prevalence of heart disease can be calculated as:
        
[Eq. 2]
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8Eq. 2 expresses the total prevalence of HD in terms of  and  
using the value of AD prevalence, . Regardless of which equation to use, the split should 
be the same as  and  represent the same coloured area in 
Figure S2.2 although the actual figures of the conditional probabilities differ depending on which 
disease status is assumed to be known. 
Figure S2.2. Prevalence linkage between AD and heart disease
However, Eq. 2 could not be used as the total prevalence of heart disease had to be partitioned 
among the cardiac events included in the model and data required for using Eq. 2 were not available 
from the literature searches.  Hence, the prevalence of AD was divided into the prevalence of AD for 
people with and without HD using Eq. 1.
Using Bayes theorem,  in Eq. 1 was calculated as 
  [Eq. 3]. The relationship in Eq. 1 was used to 
calculate .  The following sections describe the methodology and report the 
calculation results. 
Calculation and calibration of the prevalence of Alzheimers disease among heart disease patients
The prevalence of AD among people with HD, , was calculated by combining the 
results on  and  using Eq. 3. Subsequently, the prevalence of AD 
among people without HD, ,  was also estimated using Eq. 1. 
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in Table S2.1. These values were used in the linked model as the prevalence of AD in relation to the 
presence of heart disease. The ratio   varied with age group and sex as the prevalence 
of individual diseases,  and , differ between age and sex. 
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Table S2.1. Prevalence of AD divided into the prevalence for people with HD and that for people 
without HD (before calibration8
Prevalence of AD
 People with HD M People without HD  Ratio 5M1N6
Age Men Women Men Women Men Women
<65 0 0 0 0 NA NA
65-69 0.018267 0.044718 0.006785 0.005929 2.69 7.54
70-74 0.036962 0.05099 0.015618 0.009068 2.37 5.62
75-79 0.051255 0.091056 0.032751 0.034654 1.57 2.63
80-84 0.095646 0.180764 0.058681 0.068831 1.63 2.63
85+ 0.196727 0.363585 0.108037 0.132586 1.82 2.74
The prevalence of AD before and after applying the correlations were compared using the values 
sampled at the model entry in order to see whether the estimation method used for splitting 
prevalence produced similar results. The total prevalence of AD and the prevalence for people with 
and without HD are compared in Table S2.2. The prevalence values of AD with and without HD were 
combined for comparison with the total AD prevalence before splitting using 100,000 simulated 
individuals for each age group (in order to have enough numbers of simulated individuals in each age 
group). The absolute percentage differences ranged from 0.23% to 5.09% between the total 
population values and the split values of prevalence.  The percentage difference was the largest for 
female population aged 70-74 years. The differences could be due to the use of the single estimate 
of  in Eq. 3 for all age groups and sex, which fails to reflect variation among 
different populations in the estimation equation.  
Although the differences could be considered small, the prevalence of AD split for people with and 
without HD was calibrated to match the total prevalence. Calibration was performed in order to 
start the model with the same population with respect to the total prevalence of AD. Based on the 
total prevalence values, age- and sex-specific calibration multipliers were applied to the prevalence 
values for people with and without HD. These were calculated as the total prevalence divided by the 
combined prevalence using split values. The calibrated prevalence after these multipliers were 
applied was used in all models for this paper where AD and heart disease were correlated. 
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Table S2.2. Comparison of simulated proportions of people with Alzheime9:s disea<= >?@AB C=DE=en 
when the total prevalence of AD was used and when the prevalence of AD split into HD and non-HD 
groups was used 
Total prevalence of 
AD (before splitting)
Combined 
prevalence of AD 
using split 
prevalence values*
% Difference 
(compared with the 
total prevalence AD)
Age M=G Women M=G Women M=G Women
<65 0 0 0 0 0 0
65-69 0.0101 0.0108 0.0098 0.0104 -3.01% -3.98%
70-74 0.0223 0.0158 0.0232 0.0166 3.88% 5.09%
75-79 0.0403 0.0511 0.0387 0.0503 -3.94% -1.52%
80-84 0.0734 0.1015 0.0732 0.1020 -0.38% 0.44%
85+ 0.1411 0.1980 0.1451 0.1985 2.79% 0.23%
*Based on the results of 100,000 simulated individuals for each age group. 
In order to examine the effect of the calibration at the population level, the numbers of people with 
AD across all age groups in the models before and after calibration were compared in Table S2.3 
when 200,000 individuals aged 65 years and over were simulated for each model (the age 
distribution for people aged 65 and over was adapted from the ONS mid-2012 UK population 
estimates). The total numbers of people with AD among 200,000 simulated individuals from models 
with and without calibrated prevalence values were compared with that from the model where 
heart disease and AD were independently linked. The calibration reduced the difference between 
when the total AD prevalence was applied and when the split prevalence values were used from 
0.50% to 0.24% for male population and from 1.89% to 1.18% for females. 
There still existed differences in the number of people with AD after calibration due to Monte Carlo 
sampling error. Perfect calibration would have been possible if the calibration factors were 
calculated using the model results with the infinite number of runs for each age and sex group. In 
addition, if the infinite number of individuals were simulated in the perfectly calibrated model and 
the independently linked model for figures in Table S2.3, the differences would have been 
eliminated. 
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Table S2.3. NHIJKL of individuals with AlzheimeLOs disePQK RSTU Jefore and after calibration 
compared with when total prevalence without correlations was applied
Number with AD when 
Total AD prevalence was 
used**
Number with AD when split prevalence values were used* 
(difference (n; %))
VKW Women VKW Women VKW Women
Before calibration After calibration
3378 6292
3395
(+17; +0.50%)
6411
(+119; 1.89%)
3386
(+8; 0.24%)
6366
(+74; +1.18%)
*Among 200,000 simulated individuals aged 65 years and older; **Results from the model where 
heart disease and AD were linked with independence between diseases assumed. 
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Correlation between Heart disease and Osteoporosis 
The model in this study focussed specifically on correlations regarding hip fracture, and XY Z[\ 
stroke as these events are associated with the highest costs and utility effects. This section describes 
the correlation between hip fracture and a history o] XY^ Similar calculation was performed for the 
correlation between the risk of stroke and a history of hip fracture. 
Incidence of hip fracture and prevalent cardiovascular disease
_`Zbcg`h `isks are influenced by the presence of ijk^  In a study by lh`ber and colleagues [1]m XY
was associated with higher risk of all types of osteoporotic fracture. Excess fracture risks afte
` XY
were found with the overall adjusted hazard ratio nopq t] u^vw nxyz iY u^uw{u^56) across all anatomic 
sites. Trends of the fracture incidence rates for three time-periods (1979-1989; 1990-1999; 2000-
2006) were tested and an increase in fracture rates over time was found among MI patients. An HR 
of 1.66 for both men and women for hip fracture was used in the model, which was for the most 
recent time period (2000-2006). Data reported in Gerber et al. [1] was used in the model as this 
study was based on a large sample size and similar ethnic group to that of the UK, and provided 
relatively recent data in the format suitable to be applied to the time-to-event distributions used in 
the model.  Only a transient increase of fracture risks after MI was identified in the study. In the 
Gerber et al. (2011) study, as the mean follow-up time was only 4 years and the association between 
and MI and 5-year risk of osteoporotic fracture was reported, HR was applied for five years after MI. 
The incidence of hip fracture was split between that for those with MI and that for those without. 
Using the prevalence estimates of MI used to populate the individual heart disease model, the total 
incidence of hip fracture was split between the incidence of hip fracture for patient who had an MI 
within 5 years and that for patients who did not have MI for the last 5 years. These were reported in 
Table S2.4 for those on no treatment (A) and on drug treatment for osteoporosis (B) where an RR of 
72% for hip fracture was applied [17]. Due to the low prevalence of MI among younger age groups, 
the baseline incidence for those without MI was similar to the total incidence including both groups 
with and without MI. 
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Table S2.4. Hip fracture incidence split between rates for those wi|} ~ d withou| ~
A. Hip fracture incidence with and withou| ~    |atment
 Total incidence of hip 
fracture
Ł
ne rate r (without 
~
Rate for patients with ~
Age ~ Women ~ Women ~ Women
45-50 0.00030 0.00020 0.00030 0.00020 0.00049 0.00033
50-55 0.00030 0.00020 0.00030 0.00020 0.00049 0.00033
55-60 0.00070 0.00050 0.00067 0.00049 0.00112 0.00082
60-65 0.00030 0.00080 0.00029 0.00079 0.00048 0.00131
65-70 0.00080 0.00130 0.00073 0.00127 0.00121 0.00211
70-75 0.00110 0.00210 0.00100 0.00206 0.00167 0.00341
75-80 0.00200 0.00420 0.00180 0.00396 0.00299 0.00658
80-85 0.0068 0.0097 0.00613 0.00915 0.01017 0.01519
85+ 0.0099 0.0217 0.00892 0.02047 0.01481 0.03398
B. Hip fracture incidence with and without MI  For individuals on drug treatment for 
osteoporosis
 Total incidence of hip 
fracture  on drug 
treatment
Baseline rate r (without 
MI)
Rate for patients with MI
Age Men Women Men Women Men Women
45-50 0.00025 0.00018 0.00025 0.00017 0.00041 0.00029
50-55 0.00024 0.00017 0.00024 0.00017 0.00040 0.00028
55-60 0.00050 0.00033 0.00048 0.00032 0.00080 0.00054
60-65 0.00020 0.00055 0.00019 0.00054 0.00032 0.00090
65-70 0.00060 0.00092 0.00054 0.00090 0.00090 0.00149
70-75 0.00081 0.00150 0.00074 0.00147 0.00123 0.00244
75-80 0.00145 0.00303 0.00131 0.00286 0.00217 0.00475
80-85 0.00490 0.00695 0.00442 0.00656 0.00733 0.01088
85+ 0.00713 0.01557 0.00643 0.01469 0.01067 0.02439
The incidence rates of hip fracture with and without a recent MI reported in Table S2.4 were used as 
the baseline event rates for hip fracture for the first 5 year period after MI. The relative risks 
associated with factors that can influence the event rates, such as low BMD and previous fracture, 
were applied onto these baseline rates. When sampling time to next hip fracture, these baseline 
incidence rates of hip fracture were updated when the sampled time to event was longer than the 
time before a change in age band, or the time left to a change in the drug efficacy due to the 
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treatment fall time after discontinuation. Hence, all three time intervals for which different event 
rates are applied  time to 5 years after      band, and time to next efficacy change 
due to the fall time of treatment effect  were continuously compared with the sampled time to 
event (T value. When the sampled TTE value is longer than any of the three, the baseline 
incidence rates were changed accordingly and TTE was resampled. 
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Appendix 3. Parameter estimates and data sources
Event Rates 
This section describes the event rates used for the base-case model only for HD due to the addition 
of PAD and updated parameters. Parameter estimates used in the AD and osteoporosis models were 
based on the data reported in the HTA reports [13, 17] and are detailed in Youn [15]. The data 
sources were identified from the six UK-based studies [18-23]. The most appropriate parameter 
estimates reported for similar populations and contexts in the six studies and their sources of data 
were used for the model in this research. UK-sourced data were used wherever possible, and age-
dependent time-variant rates of transitions between health events were preferred.
All included HD disease states except PAD were split into two temporal categories  first year and 
subsequent years after the event  due to the difference in the rates for transitions to other events, 
costs, and/or utility weights between the first year of the event and thereafter.  Various sources for 
cardiac death rates were used dependent on the from state of the transition. The rate of transition 
to cardiac death varied with the age group and the temporal period (first year or subsequent years 
after the event), and time to cardiac death was sampled from an exponential distribution, the 
parameter of which produced the appropriate rate. 
The event rates used in the model are summarised in the next sections by the origin of transitions, 
with each section followed by a summary table of the estimates. In addition, rates of transitions to 
fatal stroke and PAD were described in separate sections as they applied regardless of the origin of 
transitions. 
Transitions from event-free state (at model initiation)
Event rates differed depending on whether an individual is on primary or secondary prevention 
interventions, or is untreated. Rates of transitions from the event-free state are summarised in Table 
S3.1. 
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Table S3.1.  ¡¢£¤ne annual rates of transition from event-free state
Baseline rates for individuals not receiving statin treatment
From To Estimates Sources
Event free ¥¦ Rate for men = 0.01624; Rate for 
women = 0.01123
WOSCOPS 
(Shepherd et al. 
1995 [24]) and 
Framingham 
studies 
(DAgostino et al. 
2008 [25])
Stroke Exponential mean of Exp(9.218 + (-
0.064)*age at event + (-
0.176)*gender) for time to event 
distribution . Then, the 
prob of stroke being fatal applied. 
P(fatal stroke)=e^xb/[1+e^xb] where 
xb= -4.874 + 0.043*age  
0.074*gender.  
Anglo-
Scandinavian 
Cardiac Outcomes 
Trial (ASCOT) trial 
results [22]
Angina Rate = 0.0027 per patient-year. ASCOT-LLA data 
[26] 
Revascularisation For only primary and secondary 
prevention populations, 
Exponential mean of Exp(5.250 + (-
0.013)*age at event + 
(0.479)*gender) for time to event 
distribution . 
Otherwise, the national average rate 
of revascularisation was used. 
ASCOT trial [22]
National Audit of 
PCI [27]
PAD Rate= 0.021149= the incidence of 
PAD with intermittent claudication.
Edinburgh Artery 
Study [28]
CVD death For individuals not receiving any 
interventions, 
Males (females): 45-54 years 
0.000639 (0.000178); 55-64 years 
0.001711 (0.000573); 65-74 years 
0.004275 (0.001994); 75-84 years 
0.013182 (0.008621); 85 years and 
over 0.040947 (0.035576).
For only primary and secondary 
prevention populations, 
Exponential mean of Exp(6.576 + (-
0.035)*age at event + 
(0.437)*gender) for time to event 
distribution .
Mortality 
Statistics: Deaths 
registered in 2012 
[29]
ASCOT trial [22]
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§¨©ª«¬tions from MI
Table S3.2. Baseline annual rates of transitions from myocardial infarction
Baseline rates for individuals not receiving statin treatment
From To Estimate Sources
MI MI For age groups 1-5: First 
(subsequent) year(s) rates: 
0.13697 (0.01633),  
0.12239 (0.01806), 0.10747 
(0.01867), 0.09146 (0.0180), 
0.07375 (0.01613).
NICE TA94 Table 
52 [30]; 
Nottingham Heart 
Attack Register 
(NHAR) [31].
Stroke For age groups 1-5: First 
(subsequent) year(s) rates: 
Group 1 (< 55): 0.00150 (0.0004),  
Group 2 (55-65): 0.00321 (0.00100), 
Group 3 (65-75): 0.00682 (0.00220), 
Group 4 (75-85): 0.01420 (0.00471), 
Group 5 (> 85): 0.02819 (0.00914).
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR); 
Angina Exponential rate =  0.05975 Ara et al. 2009. 
Table 8 [23]; Fox et 
al. 2005 [32]
Revascularisation First year rate = 0.504347 TNT trial
[20]
PAD Rate= 0.021149= the incidence of 
PAD with intermittent claudication.
Edinburgh Artery 
Study (Leng et al. 
1996)
CVD death For age groups 1-5: First 
(subsequent) year(s) rates: 
Group 1 (< 55): 0.01755 (0.00541),  
Group 2 (55-65): 0.03387 (0.00955), 
Group 3 (65-75): 0.06465 (0.01603), 
Group 4 (75-85): 0.12059 (0.02482), 
Group 5 (> 85): 0.21791 (0.03615).
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR) 
[31].
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­®¯°±²tions from Stroke 
Table S3.3. ³´µ¶·¸ne annual rates of transitions from Stroke
Baseline rates for individuals not receiving statin treatment
From To Estimate Sources
Stroke ¹º Rates by age group: 
»¼oup ½ ¾¿ ÀÀÁÂ 0.00160,
Group 2 (55-65): 0.00310,
Group 3 (65-75): 0.00552,
Group 4 (75-85): 0.00803,
Group 5 (> 85): 0.01045.
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR) 
[31].
Stroke
(Stroke 
recurrence)
Baseline rates for 0-1, 1-5, 5-10 
years for individuals aged <65:
0-1 year rate= 0.06401 (mean = 
15.6237); 1-5 year rate= 0.02694; 5-
10 year rate= 0.01887.
Then, probability of stroke being 
fatal= e^xb/[1+e^xb], where
xb= -4.874 + 0.043*age  
0.074*gender, was applied. 
Mohan et al. 2009 
[33]  Stroke 
recurrence; ASCOT 
trial [22]
Angina Rate = 0.0027 Assumed the same 
as the rate of 
transition from 
event free to 
angina state (NICE 
TA 94 Table 52) 
Revascularisation Rate= 0.01056 TNT trial [20]
PAD Rate= 0.021149= the incidence of 
PAD with intermittent claudication.
Edinburgh Artery 
Study [28]
CVD death For age groups 1-5: First 
(subsequent) year(s) rates: 
Group 1 (< 55): 0.00924 (0.00421),  
Group 2 (55-65): 0.02245 (0.00985), 
Group 3 (65-75): 0.05340 (0.02102), 
Group 4 (75-85): 0.12466 (0.04207), 
Group 5 (> 85): 0.27839 (0.07796).
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR) 
[31]
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ÃÄÅÆÇÈtions tÉ ÊÅtal Stroke
If the reported data did not explicitly state that the event probabilities were for non-fatal stroke only, 
then a proportion of the patients who experience a stroke was assumed to die due to the stroke. 
The proportion of fatal stroke among all stroke events was estimated using the logistic regression 
ËÌÍÎÏÐon reported in the ASCOT trial results [22] with an exception of transitions from 
revascularisation state wherË Î ÑÒÓ ÔÕÖ×ability of stroke being fatal was assumed as in Ara et al. 
ØÙÒÒÚÛÜ Ý
hus, the transitions to stroke from event free, stroke, angina and revascularisation states 
included a subset of patients having a fatal event and su
×ÞËÌÍËßÏà
y moving to cardiac death state.
ÃÄÅÆÇÈtions from Angina
Rates of transitions from angina are given in Table S3.4. Individuals were assumed to have stable 
angina first and then progress to unstable angina, which rËÌÍires more intense medical treatments. 
Once unstable angina was developed, it was assumed that patients could not improve to stable 
angina. 
Page 116 of 141
21
Table S3.4. áâãäåæne annual rates of transitions from angina
Baseline rates for individuals not receiving statin treatment
From To Estimates Sources
Angina çè éê ërom Stable angina: Rate = 0.01520;
2) Unstable angina
ìíî 4.9íî ïðñíî 4.3í òrom 1st year event.
óðìíî
 6.3%, 11.2%, 18.5% from subsequent 
yrs event for those aged <55, 55-65, 65-75, 
75-85 yrs, respectively. 
Juul-Moller, 
Edvardsson [34]; 
Ara, Pandor [23], 
Table 8; Gray and 
Hampton [31]; 
Stroke 1) From Stable angina: 
Rate = 0.00791; Then, the prob of stroke 
being fatal applied, probability = 
e^xb/[1+e^xb], where xb= -4.874 + 
0.043*age  0.074*gender. 
2) From Unstable angina: For age groups of 
<65, <75, <85, >85 years,
[1st year rate] To non-fatal stroke: 0.2%, 
0.5%, 1%, 2%; To fatal stroke: 2.6%, 4.3%, 
7%, 10.3%; 
[subsequent yrs rate] To non-fatal stroke: 
0.1%, 0.1%, 0.3%, 0.7%;  Fatal stroke: 
0.4%, 0.5%, 0.6%, 0.7%.
1) Juul-Moller, 
Edvardsson [34]; 
NICE [30]; Lindgren, 
Buxton [22]
2) Ara et al. 2009 
(HTA) Table 8.; 
Gray and Hampton 
[31]
Angina 
(unstable)
Annual probability from stable angina to 
unstable angina: 
Group 1 (< 55): 0.0013,
Group 2 (55-65): 0.0029,
Group 3 (65-75): 0.0060,
Group 4 (75-85): 0.0091, 
Group 5 (> 85): 0.0122. 
NICE TA 94: Table 
52. 
Revascularisat
ion
Rate=0.00269 Assumed the same 
as the minimum 
revascularisation 
rate from PAD state. 
(Leng et al. 1996)
PAD Rate= 0.021149= the incidence of PAD with 
intermittent claudication.
Edinburgh Artery 
Study (Leng et al. 
1996)
CVD death 1) If no history of angina= 
Group 1 (< 55): 0.009, 
Group 2 (55-65): 0.0035, 
Group 3 (65-75): 0.007, 
Group 4 (75-85): 0.007, 
Group 5 (> 85): 0.007.  
2) From unstable angina = (CHD and CVD 
death rates combined for 1st and 
subsequent years.
NICE TA94 (Table 
52); Nottingham 
Heart Attack 
Register (NHAR).
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ôõö÷øùtions from Revascularisation
Table S3.5. úûüýþßne annual rates of transitions from revascularisation
Individuals not receiving statin treatment
From State To State Estimate Sources
Revascularisation M  Rate= 0.03874 Fox, Poole-Wilson 
[32]; Ara et al. 
(2009) [23]
Stroke Rate=0.002 with 50% of stroke 
being assumed to be fatal. 
Henderson, 
Pocock [35]; Ara 
et al. (2009) [23]
Angina Rate = 0.032523 Henderson et al. 
(2003); Ara et al. 
(2009) [23]
Revascularisation First-year rate  of having a 2nd 
revascularisation= 0.14491
TNT trial [20] 
PAD Rate= 0.021149= the incidence of 
PAD with intermittent claudication.
Edinburgh Artery 
Study [28]
CVD death Rate = 0.005785 RITA-2 trial [35]
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Tastions from PAD
Table S3.6.  ne rates of transitions from peripheral arterial disease
Baseline rates for individuals not receiving statin treatment
From To Estimate Sources
PAD 	
 Rate = 0.01711 Edinburgh Artery 
Study [28]
Stroke Rate= 0.01408 Edinburgh Artery 
Study [28]
Angina Rate= 0.02019 Edinburgh Artery 
Study [28]
Revascularisation Rate=0.00269 Edinburgh Artery 
Study [28]
PAD Rate=0 Assumed
CVD death Exponential mean of Exp(6.576 + (-
0.035)*age at event + 
(0.437)*gender) for time to event 
distribution .
The same rate as 
the transition 
from event free 
to CVD death: 
ASCOT trial [22]
Transitions to PAD
The incidence of PAD reported in the Edinburgh Artery Study was used for the estimation of 
transition rates to PAD. The incidence of symptomatic PAD (i.e. with intermittent claudication, IC) in 
general population aged 55 and over was used for all transitions to PAD event due to the lack of 
published evidence [28]. Age dependent incidence was not included as it was not statistically 
significant in the Edinburgh Artery Study [28]. However, there was some evidence of an increase 
with age in earlier longitudinal studies [36, 37].  
Among patients with PAD, approximately 20% progress to develop severe symptoms with critical 
limb ischaemia (CLI) over a 5-year period and 1-2% undergo amputation over a lifetime [38]. In the 
model, 20% of people with IC were randomly sampled to develop CLI at the time of developing PAD 
for simplicity, to whom higher costs and lower utility weights were applied. 
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Effectiveness of statin treatments
Statin interventions was assumed to reduce the risks of coronary events  angina, and fatal CHD 
eve and stroke. The model assumes that a proportion of individuals entering the model are 
receiving a statin intervention for primary and secondary prevention of CV eents. The relative 
r  of events associated with statin use were applied to the baseline risks converted from the 
event rates reported in Tables S3.1-S3.6, and are shown in Table S3.7.  
Table S3.7. Relative risks associated with statin use compared with placebo
Transitions to Relative Risk Source
MI 0.656 Ward et al. (2006) [18]
Non fatal stroke 0.754 Ara et al. (2009): Simvastatin 
40mg/day
Fatal stroke (from Angina 
state)
0.876 Ara et al. (2009): Simvastatin 
40mg/day
Stable Angina (from event free 
state)
0.59 Ward et al. (2006) [18]
To Fatal CHD event (CVD 
death)
0.74 Ward et al. (2006) [18]
Non CVD death (from event 
free state)
0.656 Ward et al. (2006) [18]
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Non-disease mortality
Nﬀﬁﬂﬃac mortality rates used to construct distribution profiles for time to non-disease death 
were calculated by subtracting cardiac mortality rates from the all-cause death probability profiles. 
Cardiac mortality rates were estimated by combining the rates reported for heart disease (ICD-10 
code !""!#$% ﬁﬃ stroke (I64) using data obtained from the Mortality Statistics: Deaths registered in 
2012 [29]. Cardiac mortality rates used to calculate the non-disease mortality are shown in Table 
S3.8. These were the same rates used for transitions to cardiac death from event-free state.
Figure S3.1 shows distributions for time to non-cardiac death for a few selected age groups. As the 
cardiac death rates were assumed constant across the 10-year age bands whilst the all-cause 
mortality rates were specified at every age  between 45 and 100 years, the probability profiles 
created were not smooth, but had a few stepped decreases at the age cut off values. 
Table S3.8. Cardiac death rates used to estimate non-cardiac mortality rates*
Age group
Sex 45-54 55-64 65-74 75-84 85 and 
over
Male 0.000639 0.001711 0.004275 0.013182 0.040947
Female 0.000178 0.000573 0.001994 0.008621 0.035576
*Adapted from Table 8 in Deaths registered in England and Wales, 2012 [29]
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Figure S3.1. Illustration of distributions for time to non-cardiac death
Male aged 45 years Male aged 55 years
Male 65 years Male 75 years
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Costs
Table S3.9. Cost estimates used in the base-case model
Event Data within 
source
Price year Estimates [39]
(2011/2012 price)
Original Source
&' ( )*+ ,-ar £3,996 2007  £  4,519.10 Ara et al. (2009) 
estimated using 
British National 
Formulary (2008) 
[40]
MI - subsequent 
year
£171 2004  £  214.89 NICE TA 94 (GP 
contacts + 
medication costs)
Stroke - 1st year £8,066 2007  £ 9,121.88 Ward, Lloyd-Jones 
[18]
Stroke - 
subsequent yr
£2,266 2007  £ 2,562.63 Ward, Lloyd-Jones 
[18]
Stable angina £171 2004  £ 214.89 NICE TA 94 (GP 
contacts + 
medication costs)
Documented 
angina
 £     587.07 2005  £ 713.94 Taylor et al. (2009)
Revascularisation 
- 1st yr
 £  5,857 2007  £ 6,623.71 Taylor et al. (2009); 
HRG
PAD (IC) £180 2009-
2010
£189.31 Kearns, Michaels 
[41]
PAD (CLI) £624 2009-
2010
£656.29 Kearns, Michaels 
[41]; National 
Clinical Guideline 
Centre [38]
Statin treatment £144.12 2014 £144.12 British National 
Formulary (2014); 
Estimated using the 
method by Ward et 
al. (2006)
Baseline utility values by age and gender in the UK general population were estimated from a 
statistical model reported in Ara and Brazier [42].
The utility values associated with the health states included in the model were obtained from NICE 
TA94 and the HTA report by Ara et al. (2009). Table S3.10 describes the original sources of these 
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values. All the utilities were estimated using the EQ-5D, and were assumed to be multiplicative. 
Utility multiplier values were assumed to increase by 10% after the first year of the event as 
assumed in Ara et al. (2009). It was assumed that the history of revascularisation procedure did not 
affect the utility level, and the utility decrement for stable angina was used for individuals with 
history of angina. As a base-case, deterministic values for utility multipliers were used.
Alongside the current event, the history of the other health events was incorporated in the utility 
multiplier. For example, if a man aged 65 years who has just had a stroke has a history of MI, then 
the utility decrements for both stroke (first year multiplier for stroke: 0.629) and that for MI 
(subsequent-year multiplier: 0.836) were applied to the baseline utility (0.815); the utility weight for 
this person is thus 0.429 (i.e. 0.815*0.629*0.836). 
When more than one cardiac event occurs within one year, the first-year periods of those events 
overlap. For the time periods overlapping, utility multipliers associated with the events were applied 
multiplicatively. For instance, if an individual experiences an MI at time=2.3 years and subsequently 
a stroke at time=2.7 years, then for time between 2.3 and 2.7 years, only the utility multiplier for the 
first year of MI would be applied (0.760) whilst for time between 2.7 and 3.3 years, utility multipliers 
associated with both first-year MI and first-year stroke would be applied (0.760*0.629=0.478). In the 
same way, for time between 3.3 and 3.7 years, utilities associated with subsequent years of MI and 
first year of stroke are used (0.836*0.629=0.526) In the model for this paper, whenever individuals 
reach these time points, they are directed to the utility cut off point event in order to update 
variables related to utility multiplier. 
Table S3.10. Utility multipliers by health state 
State First year - 
Mean (S.E.)
Subsequent years - Original Sources
MI 0.760 (0.018) 0.836 (10% increase) Goodacre, Nicholl [43]
Stroke 0.629 (0.04) 0.692 (10% increase) Tengs and Lin [44]
(Stable) angina 0.808 0.889 (10% increase) Melsop, Boothroyd [45]
Unstable angina 0.77 0.847 (10% increase) Goodacre, Nicholl [43]
Revascularisation 0.78 0.858 (10% increase) Serruys, Unger [46]
PAD IC 0.70 0.70 Kearns, Michaels [41]
PAD CLI 0.35 0.35 [Kearns, Michaels [41]]
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Appendix mparison of the single-disease models in this study with the published reference models
Study Model 
type 
(software)
Base-case 
Population
Intervent
ion
Compara
tor(s)
Outcomes Perspecti
ve
Time 
horizon/ 
price 
year
Health 
events 
included 
(e.g. Markov 
health 
states)
Stratified 
results 
(Yes/No)
Base-case 
ICER
Parameters driving 
ICER
Heart disease (HD)
HD single-
disease 
model in 
this paper
Discrete 
event 
simulation 
(Simul8)
General 
population 
aged 45 
years and 
over
Statins No 
statins
QALYs NHS Lifetime MI, stable 
angina, 
unstable 
angina, 
stroke, 
revascularisa
tion, PAD, 
CVD death, 
and non-
CVD death
Yes  Base-
case reported 
for the total 
population; 
and by age 
and gender, 
by prevention 
type 
1) Secondary 
prevention - 
£1.5k  
4.0k/QALY 
vary by age 
and gender
2) Primary 
prevention - 
£2.2k-2.8k 
varied by age 
and gender
Reduced cost of 
statins (updated to 
2012 values); 
Population age and 
sex distribution at 
model entry;
Added event of PAD 
could lower ICERs 
compared to the 
results from Ward 
et al. (2006) 
HD 
reference 
model by 
Ward et al. 
(2006) [18]
Markov 
model
A 
population 
with CHD 
or at 
increased 
risk of CHD 
events 
(annual 
CHD risk of 
0.5%-3%)
Statins
as a 
group
No 
statins
QALYs NHS Lifetime/
2004
Discount 
rates of 
6% for 
costs and 
1.5% for 
health 
benefits
MI, stable 
angina, 
unstable 
angina, CHD 
death, TIA, 
stroke, and 
CVD death 
or non-CVD 
death
Yes  
Base-case 
reported by 
prevention 
level, age and 
sex, and 
predicted 
annual CHD 
risk levels
Multiple base-
case values
1) Secondary 
prevention - 
£10k-£17k 
/QALY
2) Primary 
prevention  
at annual CHD 
risk of 3%, 
£10k-37k 
/QALY for 
men and 
£14k-48k 
/QALY for 
women
Results were most 
sensitive to the cost 
of
statins, discount 
rates and the 
timeframe of the 
model; Larger 
incremental costs 
than the model in 
this study;
ICERs sharply 
increased with age 
of the population
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Alzheimers disease (AD)
AD model 
in this 
paper
Discrete 
event 
simulation 
(Simul8)
General 
population 
aged 45 
years and 
over
Donepezil 
and 
memanti
ne 
BSC QALYs NHS and 
PSS
Lifetime AD onset; 
diagnosis; 
pre-
institutionali
sation; 
institutionali
sation; and 
death
Yes  results 
reported for 
two age 
groups aged 
>45 and >65 
years
Donepezil and 
memantine 
therapy 
dominated 
BSC (cost 
saving £14 
with 0.001 
QALY gain)
The model results 
were generally 
comparable with 
those from Bond et 
al. (2012).
Incremental QALYs 
from the model for 
this study were 
smaller than those 
from Bond et al. 
(2012) as the 
general population 
was modelled with 
the added events of 
the onset and 
diagnosis of AD. 
AD 
reference 
model by 
Bond et al. 
(2012) [13]
Markov 
model 
(Microsoft 
Excel)
People 
with mild, 
moderate 
or severe 
AD
donepezil
, 
galantami
ne,
rivastigmi
ne, for 
mild-to-
moderate 
AD, and 
memanti
ne, for 
moderate
-to-
severe AD
BSC QALYs NHS and 
PSS 
20 years
/ 2009 
price
pre-
institutionali
sation; 
institutionali
sation; and 
death
Yes  by 
disease 
severity 
Donepezil for 
mild-to-
moderate AD 
dominated 
BSC; 
Memantime 
for moderate-
to-severe AD: 
£32.1K/ QALY 
(increC=£405; 
increQ 
=0.013)
Results sensitive to 
assumptions on 
discontinuation 
rates; Costs of 
institutionalisation 
Osteoporosis
Osteoporo
sis model 
in this 
paper
Discrete 
event 
simulation 
(Simul8)
General 
population 
aged 45 
years and 
70mg 
alendron
ate taken 
once 
No 
alendron
ate 
treatmen
QALYs NHS and 
PSS
Lifetime Hip fracture; 
vertebral 
fracture, 
wrist 
Yes  by age 
and gender, 
BMD level, 
status of 
Alendronate  
dominated no 
treatment for 
75-year-old 
Age, BMD level and 
history of previous 
fracture altered the 
incremental costs 
Page 126 of 141
31
over weekly t fracture; 
proximal 
humerus 
fracture; 
fracture-
related 
death; non-
fracture 
death
previous 
fracture
women with 
T-score of -3 
SDs and -2.5 
SDs with no 
previous 
fracture
and QALYs. 
However, 
regardless of the 
willingness-to-pay 
threshold per QALY, 
the alendronate is 
likely to be a cost-
effective option for 
fracture prevention.
Osteoporo
sis 
reference 
model by 
Stevenson 
et al. 
(2009) [17]
Patient-
level 
./01ov 
model 
2
.
3crosoft 
E45678
Postmenop
ausal 
women 
aged 50 
years and 
over
9
3
tamin 
K: 
alendron
ate; 
risedrona
te; 
strontium
ranelate
;<
alendron
ate; next 
cost-
effective 
treatmen
t options
QALYs ;=> /?@ 
PSS
10 years 
(the 
results 
subA6BC6
ntly 
adjusted 
to 
account 
for 
treatmen
t benefits 
beyond 
the initial 
10 y
6
/0
A8
Hip fracture; 
vertebral 
fracture, 
wrist 
fracture; 
proximal 
humerus 
fracture; 
nursing 
home entry 
from hip 
fracture; 
breast 
cancer; and 
coronary 
heart 
disease; and 
non-fracture 
related 
death
Yes  by age, 
D.F
7
evel, 
and status of 
previous 
fracture
Alendronate  
dominated no 
treatment for 
75-year-old 
women with 
T-score of -3 
SDs with no 
previous 
fracture; 
£1,226/QALY 
for 75-year-
old women 
with T-score 
of -2.5 SDs. 
Age, fracture risks, 
BMD and history of 
previous fracture 
could alter the ICER 
estimates. 
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Appendix aling with stochastic uncertainty around the results 
from the linked model
Background : Gncertainty around DES model outputs can be represented by both first-order 
uncertainty, defined as stochastic variability between simulated observations assuming identical 
parameter values, and second-order uncertainty, defined as uncertainty in the parameters of the 
economic model [47]. 
Aim: The degree of first order uncertainty in the linked model was examined in order to identify the 
appropriate number of simulated individuals to ensure stable model results.  Stability was defined as 
an adoption decision being robust with sufficiently small random errors.
Method: Incremental values were computed in comparison with no treatments for all three of the 
diseases (heart disease, AlzheimHIJs disease and osteoporoLOLQ. The first-order uncertainty around 
the mean incremental cost and QALYs, incremental net monetary benefit RSMB) and cost per QALY 
gained
R
UWXQ YZL [\antified for the results from the correlated linked model for the population aged 
45 years and older. 
The jackknife approach was used to estimate a confidence interval for the mean cost per QALY with 
a reduced level of bias associated with the classical estimation of non-linear statisticL ]48, 49]. The 
standard errors of the mean results were estimated having varied the numbers of simulated 
individuals ranging from 1,000 to 700,000.  The jackknife 95% confidence interval for the mean CPQ 
and the NMB results with more than 400,000 simulated individuals were derived using R 
programming language (R version 3.2.1, © The R Foundation) due to limited capacity of the 
spreadsheet software. Jackknifing execution time for the data from 700,000 simulated individuals 
was 4.69 hours on an Intel ® Core  i5 CPU 2.30 GHz processor with 4.00 GB of RAM (3.54 hours for 
600,000 data points). 
Results: Figure S5.1 shows that the incremental cost and QALYs stabilised when more than 200,000 
individuals were simulated. The standard errors of the mean NMB and CPQ started to stabilise after 
running more than 500,000 simulated individuals. The chosen number of individuals to simulate was 
700,000 for the base-case all-disease linked models (with and without correlations) in order to 
further reduce the variability of the results. 
Page 128 of 141
33
Figure S5.1. ^_rst order uncertainty in relation to the number of patients simulated in the all-disease 
linked model with correlations (base-year population aged 45 years and ov`df
gf hi
cremental cost (compared with none of the three trejkl`ikmf
nio_scounted Discounted
pf hi
cremental QALYs (compared with none of the treatments for the three d_m`jm`mf
nio_scounted Discounted
qf uvst per QALYm wxyz {j|}knife confidence inted~jf
nio_scounted Discounted
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4) Net monetary benefit (£20,000 threshold)
Undiscounted Discounted
Each figure includes error bars showing the standard error in the mean estimates of (incremental) cost and 
QALYs.
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Appendix mary of the results from the individual disease models for comparison

Heart disease only model

Alzheims disease only model

Osteoporosis only model

Sum of 
incremental values 
acro



Treatment Ł
treatment
Incremental 
value 
Treatment Ł
treatment
Incremental 
value 
Treatment Ł
treatment
Incremental 
values (C







Cost - 
Discounted
£ 8,091 £ 7,569 £ 522 £4,582 £4,596 -£ 14 £ 2,847 £ 2,947 -£ 100 £ 408
QALYs - 
Discounted
9.249 8.978 0.271 10.642 10.641 0.001 11.191 11.184 0.008 0.280
Cost £ 14,224 £ 13,197 £ 1,027 £8,845 £8,869 -£ 23 £ 6,151 £ 6,324 -£ 173 £ 831
QALYs 13.843 13.257 0.586 16.548 16.545 0.003 17.759 17.751 0.009 0.597
Life years 
lived
21.319 20.319 1.000 21.653 21.650 0.003 23.530 23.525 0.004 1.007
ICER  
Discounted 
£ 1,926 
/QALY
Dominating Dominating £ 1,458 /QALY
ICER £ 1,754 / 
QALY
Dominating Dominating £ 1,391 / QALY
HD: based on n=200,000; AD n=200,000; Osteoporosis n=400,000
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Appendix scenario with similar levels of  gains 
assumed for all three interventions
In order to examine the effect of sampling error when all three treatments have a similar level of 
QALY gains, the scenarios in Table S7.1 were assumed: these are not meant to provide accurate 
evaluations of current treatments but to show that the results would have face validity when QALY 
gains are comparable. For all three individual diseases, populations aged 65 years and older were 
simulated. Scenarios for larger QALY gains for AD and osteoporosis and reduced QALY gain for HD 
were explored. Table S7.1 shows the scenario assumptions applied to each of the three disease 
models in comparison with the base-case assumptions. 
Table S7.1. Comparison of scenario assumptions and base-case assumptions
Base-case assumptions Scenario assumptions
1. Heart disease model
Relative risks were assumed to be 0.656, 
0.754, 0.876, 0.59, 0.74, and 0.656 for MI, 
non-fatal stroke, fatal stroke, stable angina, 
fatal CHD, and non-cardiac death, 
respectively. 
Relative risks of 0.98 for statin treatment 
were assumed for all events. 
Utility values for MI, stroke and 
revascularisation were set to 0.76, 0.629, and 
0.78, respectively.
Utility values for MI, stroke, and 
revascularisation were reduced to 0.5.
2. Alzheimers disease model 
4% of monthly treatment discontinuation 
rate was assumed. 
Lifetime treatment: No treatment 
discontinuation was assumed
6 months duration of treatment effect was 
assumed.
Lifetime treatment effect was assumed.
Utility value for institutionalised individuals 
was 0.33.
Utility value for those institutionalised was 
reduced to 0.1
The average annual improvements in MMSE 
score were 2.48 for donepezil and 1.4 for 
memantine per year. 
Double treatment effect on MMSE score: 
the average improvements in MMSE score 
were set to 4.96 for donepezil and 2.8 for 
memantine per year. 
Some individuals are institutionalised at 
model entry, and some patients are 
institutionalised immediately after diagnosis.
No individuals start at the 
institutionalisation state at model entry, nor 
get institutionalised immediately after the 
diagnosis (i.e. No individuals move to the 
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institutionalisation event from the diagnosis 
event with zero time passed.
3. Osteoporosis model
Relative risks of fracture for alendronate 
treatment were set to 0.72, 0.58, and 0.82 
for hip, vertebral, and other fractures, 
respectively. 
Relative risks were assumed to be 0.33 for 
all fracture types. 
5 years of treatment duration was assumed. Lifetime treatment duration was assumed. 
Table S7.2 compares incremental outcomes from the three individual disease models with those for 
each of the individual treatments from the linked model where the diseases were assumed to be 
independent. Under the hypothetical scenarios, a comparable magnitude of QALY gains across all 
three individual disease models (Table S7.2 Column a) was achieved.  The margins of error around 
incremental costs and QALYs at 95% confidence level are shown in brackets. 
Table S7.2 reports results under the scenarios in Table S7.1, assuming the diseases were 
independent. When none of the treatments have much larger impact on QALYs gained the linked 
model produced similar results to those from the individual disease models. This shows the 
robustness of the adoption decision within the linked model for individual treatments.  
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Table S7.2. Cost-effectiveness results under larger QALY gain scenarios for individual treatments 
from the individual disease models and the independently linked model
1. Heart disease
a. Individual heart 
disease model
b. Independently linked model (n=700,000)
Incremental values 
(Margin of error) 
All 
treatments
No HD 
treatment*
Incremental 
values
DCost £ 683 (£ 66) £ 11,001 £ 10,201 £ 800
DQALYs 0.0539 (0.0179) 4.9232 4.8784 0.0448
TCost £ 913 (£ 94) £ 15,499 £ 14,380 £ 1,119
TQALYs 0.0875 (0.0267) 6.2589 6.1861 0.0728
ICER (disc.) £ 12,665 £ 17,878
ICER £ 10,433 £ 15,360
2. Alzheimers disease (AD)
a. Individual AD 
model
b. Independently linked model (n=700,000)
Incremental values 
(Margin of error) 
All 
treatments
No AD 
treatment*
Incremental 
values
DCost -£ 4,551 (£ 93) £ 11,001 £ 15,413 -£ 4,412
DQALYs 0.0508 (0.0020) 4.9232 4.8855 0.0377
TCost -£ 6,319 (£ 130) £ 15,499 £ 21,582 -£ 6,083
TQALYs 0.0688 (0.0028) 6.2589 6.2089 0.0500
ICER (disc.) Dominating Dominating
ICER Dominating Dominating
3. Osteoporosis
a. Individual 
osteoporosis 
model
b. Independently linked model (n=700,000)
Incremental values
(Margin of error) 
All 
treatments
No osteoporosis 
treatment*
Incremental 
values
DCost -£ 1,186 (£ 74) £ 11,001 £ 11,983 -£ 982
DQALYs 0.0545 (0.0128) 4.9232 4.8918 0.0314
TCost -£ 1,856 (£ 123) £ 15,499 £ 16,970 -£ 1,471
TQALYs 0.0900 (0.0204) 6.2589 6.2090 0.0499
ICER (disc.) Dominating Dominating 
ICER Dominating Dominating
 Based on n=200,000 for HD and AD models; and n=400,000 for osteoporosis model, as in the base-case;  Margin of error 
at 95% confidence level; *The other two default treatments were assumed to be available; D=discounted.
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When all the individual disease models produce similar QALY gains (without any disease with a 
significantly larger i e i  nte Carlo error for one disease on the incremental 
outcomes and cost-effectiveness of the other diseases can be much less influential. one of the 
margin of error estimates in Table S7.2 (0.0179, 0.0020, and 0.0128 for HD, AD, and osteoporosis 
models, respectively) will have a significant effect that changes the +/- signs of the values on the 
incremental QALY results from the linked model (0.0448, 0.0377, and 0.0314 for HD, AD, and 
osteoporosis treatments, respectively).  Hence, when QALY gains are similar across all diseases, the 
results are less susceptible to sampling error from the other diseases. The base-case estimated very 
small QALY gains for AD and osteoporosis treatments which could fluctuate between positive and 
non-positive values due to the sampling error associated with the treatment for HD. In cases where 
QALY gains are similar, however, the proposed methods of linking individual disease models are 
likely to produce more accurate cost-effectiveness estimates for individual treatments. 
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Appendix babilistic sensitivity analysis of the correlated linked 
model results
The correlated linked model for the three diseases (HD, AD and osteoporos was built 
probabilistically to take account of the uncertainty around input parameter point estimates. This 
section provides probabilistic results in order to show the feasibility of probabilistic sensitivity 
analysis (PSA using the linked model described in this paper. 
A probability distribution was defined for selected input parameters. The selection of parametric 
distributions was based on the nature of the d ¡ ¢ £or example, utilities were assumed beta-
distributed as the data were assumed to be bounded by zero and one. Wherever possible, 
probabilistic distributions reported in the original publications of the reference models [13, 17, 18] 
were used. Where this was not possible, the distribution was parameterised using estimates of the 
error around mean or assumed standard errors for the purpose of this feasibility run of PSA.  Table 
S8.1 shows the PSA input parameters and their distributional properties. 
Table S8.1. Variables and distributions used in the probabilistic sensitivity analysis (PSA)
PSA Variable Point estimate* Distribution Distributional properties
¤¥¦§¦¨©¥ eªª«¨¬¦­«§«®®
RR of statin treatment for 
MI
0.656 Lognormal Lognormal(logmean=-0.4219, 
logSE=0.0233)
RR of statin treatment for 
stroke
0.754 Lognormal Lognormal(logmean=-0.2826, 
logSE=0.0203)
Change in MMSE when using 
Donepezil 10mg 
1.24** Normal Normal(1.24, 0.22)
Change in MMSE when using 
Memantine 20mg
0.70** Normal Normal(0.70, 0.35)
Proportion of patients 
compliant to medication
0.75 Beta Beta(13.31, 4.44)
¯¬¦¥¦¬¦«® °ª hea¥¬± ®¬©te®
Stable angina 0.808 Beta Beta(86.00, 20.44)
Unstable angina 0.77 Beta Beta(93.67, 27.98)
MI 0.76 Beta Beta(427.09, 134.87)
Stroke 0.628 Beta Beta(91.07, 53.94)
MMSE: 0-9 0.33 Beta Beta(36.59, 74.28)
MMSE: 10-14 0.49 Beta Beta(78.04, 81.22)
MMSE: 15-20 0.5 Beta Beta(856.27, 856.27)
MMSE: 21-25 0.64 Beta Beta(1137.19, 639.67)
MMSE: 26-30 0.69 Beta Beta(282.51, 126.92)
Institutionalised 0.33 Beta Assumed the same as the utility 
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value for ²²³E:0-9
´µ¶·µbral fracture  1st year 0.626 Beta Beta(14.03, 8.38)
Vertebral fracture   
subsequent year
0.909 Beta Beta(6.61, 0.66)
Hip fracture   1st year 0.792 Beta Beta(12.26, 3.22)
Hip fracture  subsequent 
year
0.813 Beta Beta(11.55, 2.66)
¸¹º»º
Cost of institutionalisation £2941 Normal Normal(2941, 108)
Cost of death from hip 
fracture
£9525.86 Gamma Gamma(scale=67.19, 
shape=141.78)***
MMSE: mini mental score examination; *mean values used in base-case analysis; **6month 
estimate; ***calculated from assumed standard error of 800.
The probabilistic model results are shown in Table S8.2 based on 300 PSA runs in each of which 
700,000 individuals were simulated. The mean cost and QALYs of the PSA results in Table S8.2 
showed comparable results with the base-deterministic results from the correlated linked model 
albeit not identical. All of the PSA samples in Figure S8.1 showed cost per QALY being lower than the 
threshold of £20,000 per QALY gained. 
Table S8.2. Comparison of probabilistic model results with the base-case deterministic results*
Deterministic results Probabilistic resultsAll-disease 
linked 
model with 
correlations
All three 
treatments 
assumed
None of 
the three 
treatments 
assumed
Incremental 
values
All three 
treatments 
assumed
None of 
the three 
treatments 
assumed
Incremental 
values
Mean cost £14,741 £13,894 £847 £14,392 £13,575 £816
Mean 
QALYs
8.962 8.725 0.236 8.972 8.731 0.241
ICER £3,583/QALY £3,391/QALY**
*Based on 300 PSA runs; each deterministic run is based on 700,000 simulated individuals; 
**Jackknife 95% C.I. £3,360-£3,423.
Figure S8.1. Probabilistic sensitivity analysis scatterplot of incremental costs and QALYs
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                      *Based on 300 PSA runs
The results show that the adoption decision is robust when assuming the willingness-to-pay 
threshold of £20,000 per QALY gained. Each deterministic run of 700,000 individuals took 
approximately 15 minutes to run and hence, conducting 300 PSA runs for each intervention arm 
took 1.9 days of computing time (Intel CoreTM i7CPU 3.40GHz processor with 16GB RAM). Such time 
scales indicate it is feasible to conduct PSA using the multi-disease linked model. The probabilistic 
analysis of discrete event simulation model will become more achievable by using a computer with 
more processing power or parallel computing. The number of runs required would be affected by 
the homogeneity of the population studied. Hence, the use of a more narrowly defined population 
with specific characteristics and higher disease prevalence, than the general population adopted in 
the current analysis, would accelerate convergence due to higher number of disease events 
simulated and more homogeneous parameter values. 
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